GenCore version 4.5

OM nucleic - nucleic search, using sw model

Run on: August 25, 2002, 05:12:45 ; Search time 203.5 Seconds
(without alignments)
9044.385 Million cell updates/sec

Title: US-09-811-118-2
Perfect score: 1072
Sequence: 1 GACGCCGCCACCTCCGGAAC.....TTGCATCCAACATGAATTTC 1072

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 1736436 seqs, 858457221 residues

Total number of hits satisfying chosen parameters: 3472872

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : N_Geneseq_032802:*
1: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA1980.DAT:*
2: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA1981.DAT:*
3: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA1982.DAT:*
4: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA1983.DAT:*
5: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA1984.DAT:*
6: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA1985.DAT:*
7: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA1986.DAT:*
8: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA1987.DAT:*
9: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA1988.DAT:*
10: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA1989.DAT:*
11: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA1990.DAT:*
12: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA1991.DAT:*
13: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA1992.DAT:*
14: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA1993.DAT:*
15: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA1994.DAT:*
16: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA1995.DAT:*
17: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA1996.DAT:*
18: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA1997.DAT:*
19: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA1998.DAT:*
20: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA1999.DAT:*
21: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA2000.DAT:*
22: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA2001A.DAT:*
23: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA2001B.DAT:*
24: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA2002.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
	1	1072	100.0	1072	22	AAH46980	Human glutathione
	2	1068.4	99.7	1321	21	AAC98225	Human colon cancer
	3	1067.2	99.6	1205	22	AAI59813	Human polynucleoti
	4	1067.2	99.6	1228	22	AAH14527	Human cDNA sequenc
	5	1067.2	99.6	1511	22	AAH72778	Human cervical can
	6	1065.6	99.4	1315	22	AAF81788	Human secreted pro
	7	1064.2	99.3	1227	21	AAZ65013	Membrane-bound pro
	8	1064.2	99.3	1227	22	AAS46137	Human DNA encoding
	9	1064.2	99.3	1227	22	AAF44159	Human PRO828 (UNQ4
	10	1063.2	99.2	1100	22	AAI58027	Human polynucleoti
	11	846.8	79.0	872	22	AAH06810	Human cDNA clone (
c	12	406.2	37.9	751	22	AAH71016	Human cervical can
c	13	360.2	33.6	528	22	AAH11842	Human cDNA clone (
c	14	356	33.2	468	22	AAH72087	Human cervical can
	15	169.8	15.8	1342	21	AAA96342	cDNA encoding a no
	16	169.8	15.8	1342	22	AAS46159	Human DNA encoding
	17	169.8	15.8	1345	22	AAI60677	Human polynucleoti
	18	169.8	15.8	1349	21	AAA78428	Human secreted pro
	19	169.8	15.8	1417	22	AAI58891	Human polynucleoti
	20	158.8	14.8	1362	21	AAA78396	Human secreted pro
c	21	157.6	14.7	1916	22	AAL26635	Human breast cance
	22	155.4	14.5	514	21	AAA44042	Human secreted exp
	23	113.4	10.6	386	21	AAC07552	Human secreted pro
	24	110.2	10.3	472	21	AAZ42970	Human 5' EST isola
	25	91.8	8.6	515	21	AAC41358	Zea mays DNA fragm
	26	91.6	8.5	720	14	AAQ53372	Sequence encoding
	27	91	8.5	773	21	AAF08001	Fusarium venenatum
	28	84.4	7.9	552	21	AAZ38987	Escherichia coli b
	29	84	7.8	904	21	AAC40053	Arabidopsis thalia
	30	82.6	7.7	498	22	AAC85887	MST-37g1 cDNA. My
	31	82.6	7.7	2500	22	AAC85886	MST-37 cDNA. Myco
	32	82.4	7.7	889	21	AAC38471	Arabidopsis thalia
	33	81.8	7.6	829	21	AAC39100	Arabidopsis thalia
	34	81.8	7.6	899	21	AAC47317	Arabidopsis thalia
	35	80.2	7.5	441	21	AAC69759	Human breast tumou
	36	80.2	7.5	917	21	AAC77635	Human cancer assoc
	37	79	7.4	903	21	AAC37412	Arabidopsis thalia
	38	78	7.3	832	9	AAN80914	Sequence encoding
	39	78	7.3	832	16	AAQ80053	Glutathione peroxi
	40	78	7.3	832	17	AAT12329	Human glutathione
	41	78	7.3	832	18	AAT43251	Human glutathione
	42	77	7.2	761	17	AAT37365	Rat phospholipid h
	43	76.4	7.1	545	21	AAC98372	Human colon cancer
	44	76.4	7.1	928	20	AAZ41381	Human normal uteru
	45	76.4	7.1	1134	9	AAN80988	Human glutathionin

ALIGNMENTS

RESULT 1
AAH46980
ID AAH46980 standard; cDNA; 1072 BP.
XX
AC AAH46980;
XX
DT 29-OCT-2001 (first entry)
XX
DE Human glutathione peroxidase (GPx6) encoding cDNA.
XX
KW Glutathione peroxidase; GPx6; anti-human immunodeficiency virus; HIV;
KW antiinflammatory; antiallergic; antiasthmatic; antiatherosclerotic;
KW antianemic; antithyroid; immunosuppressive; antidiabetic; nephrotropic;
KW antigout; neuroprotective; osteopathic; antirheumatic; antiarthritic;
KW tranquilizer; vulnerary; antiarteriosclerotic; hepatotropic; human;
KW antipsoriatic; cytostatic; ss.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT CDS 26..589
FT /*tag= a
FT /product= "GPx6"
XX
PN US6231853-B1.
XX
PD 15-MAY-2001.
XX
PF 01-JUN-1998; 98US-0088549.
XX
PR 01-JUN-1998; 98US-0088549.
XX

```
PA   (INCY-) INCYTE PHARM INC.
XX
PI   Hillman JL,  Corley NC,  Patterson C;
XX
DR   WPI; 2001-335067/35.
DR   P-PSDB; AAB85575.
XX
PT   New substantially purified human glutathione peroxidase polypeptide,
PT   useful for diagnosing, treating or preventing reproductive disorders,
PT   immune disorders and cell proliferative or developmental disorders -
XX
PS   Example 1; Fig 1A-C; 26pp; English.
XX
CC   This cDNA encodes a human glutathione peroxidase (GPx6) polypeptide. The
CC   GPx6 polypeptide is useful for diagnosing, treating or preventing
CC   disorders associated with expression of GPx6, where the disorders are
CC   selected from reproductive disorders, immune disorders such as acquired
CC   immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory
CC   distress syndrome, allergies, asthma, atherosclerosis, anemia, autoimmune
CC   thyroiditis, bronchitis, diabetes mellitus, glomerulonephritis,
CC   Goodpasture's syndrome, gout, multiple sclerosis, myasthenia gravis,
CC   osteoporosis, rheumatoid arthritis, cancer, infections and trauma, and
CC   cell proliferative or development disorders such as arteriosclerosis,
CC   cirrhosis, psoriasis, cancer, Cushing's syndrome, and Syndenham's chorea.
CC   GPx6 is also useful to produce antibodies, and to screen libraries of
CC   pharmaceutical agents to identify those which specifically binds GPx6.
XX
SQ   Sequence 1072 BP; 275 A; 294 C; 270 G; 233 T; 0 other;


  Query Match             100.0%;  Score 1072;  DB 22;  Length 1072;
  Best Local Similarity   100.0%;  Pred. No. 1.5e-281;
  Matches 1072;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1 GACGCCGCCACCTCCGGAACAAGCCATGGTGGCGGCGACGGTGGCAGCGGCGTGGCTGCT 60
Db       1 gacgccgccacctccggaacaagccatggtggcggcgacggtggcagcggcgtggctgct 60

Qy      61 CCTGTGGGCTGCGGCCTGCGCGCAGCAGGAGCAGGACTTCTACGACTTCAAGGCGGTCAA 120
Db      61 cctgtgggctgcggcctgcgcgcagcaggagcaggacttctacgacttcaaggcggtcaa 120

Qy     121 CATCCGGGGCAAACTGGTGTCGCTGGAGAAGTACCGCGGATCGGTGTCCCTGGTGGTGAA 180
Db     121 catccggggcaaactggtgtcgctggagaagtaccgcggatcggtgtccctggtggtgaa 180

Qy     181 TGTGGCCAGCGAGTGCGGCTTCACAGACCAGCACTACCGAGCCCTGCAGCAGCTGCAGCG 240
Db     181 tgtggccagcgagtgcggcttcacagaccagcactaccgagccctgcagcagctgcagcg 240

Qy     241 AGACCTGGGCCCCCACCACTTCAACGTGCTCGCCTTCCCCTGCAACCAGTTTGGCCAACA 300
Db     241 agacctgggcccccaccacttcaacgtgctcgccttcccctgcaaccagtttggccaaca 300

Qy     301 GGAGCCTGACAGCAACAAGGAGATTGAGAGCTTTGCCTGCCGCACCTACAGTGTCTCATT 360
Db     301 ggagcctgacagcaacaaggagattgagagctttgcctgccgcacctacagtgtctcatt 360

Qy     361 CCCCATGTTTAGCAAGATTGCAGTCACCGGTACTGGTGCCCATCCTGCCTTCAAGTACCT 420
Db     361 ccccatgtttagcaagattgcagtcaccggtactggtgcccatcctgccttcaagtacct 420

Qy     421 GGCCCAGACTTCTGGGAAGGAGCCCACCTGGAACTTCTGGAAGTACCTAGTAGCCCCAGA 480
Db     421 ggcccagacttctgggaaggagcccacctggaacttctggaagtacctagtagccccaga 480

Qy     481 TGGAAAGGTGGTAGGGGCTTGGGACCCAACTGTGTCAGTGGAGGAGGTCAGACTCCAGAT 540
Db     481 tggaaaggtggtaggggcttgggacccaactgtgtcagtggaggaggtcagactccagat 540

Qy     541 CACAGCGCTCGTGAGGAAGCTCATCCTACTGAAGCGAGAAGACTTATAACCACCGCGTCT 600
Db     541 cacagcgctcgtgaggaagctcatcctactgaagcgagaagacttataaccaccgcgtct 600

Qy     601 CCTCCTCCACCACCTCATCCCGCCCACCTGTGTGGGGCTGACCAATGCAAACTCAAATGG 660
Db     601 cctcctccaccacctcatcccgcccacctgtgtggggctgaccaatgcaaactcaaatgg 660

Qy     661 TGCTTCAAAGGGAGAGACCCACTGACTCTCCTTCCTTTACTCTTATGCCATTGGTCCCAT 720
Db     661 tgcttcaaagggagagacccactgactctccttcctttactcttatgccattggtcccat 720

Qy     721 CATTCTTGTGGGGGAAAAATTCTAGTATTTTGATTATTTGAATCTTACAGCAACAAATAG 780
Db     721 cattcttgtgggggaaaaattctagtattttgattatttgaatcttacagcaacaaatag 780

Qy     781 GAACTCCTGGCCAATGAGAGCTCTTGACCAGTGAATCACCAGCCGATACGAACGTCTTGC 840
Db     781 gaactcctggccaatgagagctcttgaccagtgaatcaccagccgatacgaacgtcttgc 840

Qy     841 CAACAAAAATGTGTGGCAAATAGAAGTATATCAAGCAATAATCTCCCACCCAAGGCTTCT 900
Db     841 caacaaaaatgtgtggcaaatagaagtatatcaagcaataatctcccacccaaggcttct 900

Qy     901 GTAAACTGGGACCAATGATTACCTCATAGGGCTGTTGTGAGGATTAGGATGAAATACCTG 960
Db     901 gtaaactgggaccaatgattacctcatagggctgttgtgaggattaggatgaaatacctg 960

Qy     961 TGAAAGTGCCTAGGCAGTGCCAGCCAAATAGGAGGCATTCAATGAACATTTTTTGCATAT 1020
Db     961 tgaaagtgcctaggcagtgccagccaaataggaggcattcaatgaacatttttgcatat 1020

Qy    1021 AAACCAAAAAATAACTTGTTATCAATAAAAACTTGCATCCAACATGAATTTC 1072
Db    1021 aaaccaaaaaataacttgttatcaataaaaacttgcatccaacatgaatttc 1072


RESULT   2
AAC98225
ID   AAC98225 standard; cDNA; 1321 BP.
XX
AC   AAC98225;
XX
DT   09-MAR-2001  (first entry)
XX
DE   Human colon cancer antigen nucleotide sequence SEQ ID NO:235.
XX
KW   Human; colon cancer; colon cancer antigen; diagnosis; detection;
KW   identification; cytostatic; cardioactive; neuroprotective; vulnerary;
KW   immunomodulatory; muscular; gynaecological; gastrointestinal;
KW   nephrotropic; antiinfective; antibacterial; gene therapy; wound;
KW   neural disorder; immune system disorder; muscular disorder;
KW   reproductive disorder; gastrointestinal disorder; renal disorder;
KW   infectious disease; cardiovascular disorder; ss.
XX
OS   Homo sapiens.
XX
PN   WO200055351-A1.
XX
PD   21-SEP-2000.
XX
PF   08-MAR-2000; 2000WO-US05883.
XX
PR   12-MAR-1999;   99US-0124270.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Rosen CA,  Ruben SM;
XX
DR   WPI; 2000-587534/55.
DR   P-PSDB; AAB53468.
XX
PT   Colon cancer associated gene sequences, referred to as colon cancer
PT   antigens, useful for the treatment, prevention, and diagnosis of colon
PT   disorders such as colon cancer -
XX
```

```
PS   Claim 1; Page 656-657; 2104pp; English.
XX
CC   AAC97991 to AAC98763 encode the human colon cancer associated proteins,
CC   called human colon cancer antigens, given in AAB53234 to AAB54006. The
CC   human colon cancer antigens can have cytostatic, cardioactive, muscular;
CC   neuroprotective, immunomodulatory, gynaecological, gastrointestinal,
CC   vulnerary, nephrotropic, antiinfective and antibacterial activities, and
CC   can be used in gene therapy. The colon cancer antigen polynucleotides,
CC   proteins and antibodies to the proteins are useful for the prevention,
CC   treatment and diagnosis of colon disorders, such as colon cancer. The
CC   polynucleotides may be used in diagnostics and research, such as for
CC   chromosome identification, and as hybridisation probes. The proteins
CC   may also be used to prevent diseases such as neural disorders, immune
CC   system disorders, muscular disorders, reproductive disorders,
CC   gastrointestinal disorders, wounds, renal disorders, infectious
CC   diseases, and cardiovascular disorders. AAC98764 to AAC98772 and
CC   AAB54007 represent sequences used in the exemplification of the present
CC   invention.
XX
SQ   Sequence 1321 BP; 420 A; 326 C; 296 G; 276 T; 3 other;

  Query Match             99.7%;  Score 1068.4;  DB 21;  Length 1321;
  Best Local Similarity   99.7%;  Pred. No. 1.5e-280;
  Matches 1069;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1 GACGCCGCCACCTCCGGAACAAGCCATGGTGGCGGCGACGGTGGCAGCGGCGTGGCTGCT 60
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       5 gacgccgccacctccggaacaagccatggtggcggcgacggtggcagcggcgtggctgct 64

Qy      61 CCTGTGGGCTGCGGCCTGCGCGCAGCAGGAGCAGGACTTCTACGACTTCAAGGCGGTCAA 120
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      65 cctgtgggctgcggcctgcgcgcagcaggagcaggacttctacgacttcaaggcggtcaa 124

Qy     121 CATCCGGGGCAAACTGGTGTCGCTGGAGAAGTACCGCGGATCGGTGTCCCTGGTGGTGAA 180
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     125 catccggggcaaactggtgtcgctggagaagtaccgcggatcggtgtccctggtggtgaa 184

Qy     181 TGTGGCCAGCGAGTGCGGCTTCACAGACCAGCACTACCGAGCCCTGCAGCAGCTGCAGCG 240
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     185 tgtggccagcgagtgcggcttcacagaccagcactaccgagccctgcagcagctgcagcg 244

Qy     241 AGACCTGGGCCCCCACCACTTCAACGTGCTCGCCTTCCCCTGCAACCAGTTTGGCCAACA 300
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     245 agacctgggcccccaccacttcaacgtgctcgccttcccctgcaaccagtttggccaaca 304

Qy     301 GGAGCCTGACAGCAACAAGGAGATTGAGAGCTTTGCCTGCCGCACCTACAGTGTCTCATT 360
           |||||||||||||||||||||||||||||||| ||||||||||||||||||||||||||
Db     305 ggagcctgacagcaacaaggagattgagagctttgcccgccgcacctacagtgtctcatt 364

Qy     361 CCCCATGTTTAGCAAGATTGCAGTCACCGGTACTGGTGCCCATCCTGCCTTCAAGTACCT 420
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     365 ccccatgtttagcaagattgcagtcaccggtactggtgcccatcctgccttcaagtacct 424

Qy     421 GGCCCAGACTTCTGGGAAGGAGCCCACCTGGAACTTCTGGAAGTACCTAGTAGCCCCAGA 480
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     425 ggcccagacttctgggaaggagcccacctggaacttctggaagtacctagtagccccaga 484

Qy     481 TGGAAAGGTGGTAGGGGCTTGGGACCCAACTGTGTCAGTGGAGGAGGTCAGACTCCAGAT 540
           |||||||||||||||||||||||||||||||||||||||||||||||| ||||||
Db     485 tggaaaggtggtaggggcttgggacccaactgtgtcagtggaggaggtcagaccccagat 544

Qy     541 CACAGCGCTCGTGAGGAAGCTCATCCTACTGAAGCGAGAAGACTTATAACCACCGCGTCT 600
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     545 cacagcgctcgtgaggaagctcatcctactgaagcgagaagacttataaccaccgcgtct 604

Qy     601 CCTCCTCCACCACCTCATCCCGCCCACCTGTGTGGGGCTGACCAATGCAAACTCAAATGG 660
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     605 cctcctccaccacctcatcccgcccacctgtgtggggctgaccaatgcaaactcaaatgg 664

Qy     661 TGCTTCAAAGGGAGAGACCCACTGACTCTCCTTCCTTTACTCTTATGCCATTGGTCCCAT 720
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     665 tgcttcaaagggagagacccactgactctccttcctttactcttatgccattggtcccat 724

Qy     721 CATTCTTGTGGGGGAAAAATTCTAGTATTTTGATTATTTGAATCTTACAGCAACAAATAG 780
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     725 cattcttgtgggggaaaaattctagtattttgattatttgaatcttacagcaacaaatag 784

Qy     781 GAACTCCTGGCCAATGAGAGCTCTTGACCAGTGAATCACCAGCCGATACGAACGTCTTGC 840
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     785 gaactcctggccaatgagagctcttgaccagtgaatcaccagccgatacgaacgtcttgc 844

Qy     841 CAACAAAAATGTGTGGCAAATAGAAGTATATCAAGCAATAATCTCCCACCCAAGGCTTCT 900
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     845 caacaaaaatgtgtggcaaatagaagtatatcaagcaataatctcccacccaaggcttct 904

Qy     901 GTAAACTGGGACCAATGATTACCTCATAGGGCTGTTGTGAGGATTAGGATGAAATACCTG 960
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     905 gtaaactgggaccaatgattacctcatagggctgttgtgaggattaggatgaaatacctg 964

Qy     961 TGAAAGTGCCTAGGCAGTGCCAGCCAAATAGGAGGCATTCAATGAACATTTTTTGCATAT 1020
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     965 tgaaagtgcctaggcagtgccagccaaataggaggcattcaatgaacatttttgcatat 1024

Qy    1021 AAACCAAAAAAATAACTTGTTATCAATAAAAACTTGCATCCAACATGAATTTC 1072
           |||:||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1025 aaamcaaaaaataacttgttatcaataaaaacttgcatccaacatgaatttc 1076

RESULT   3
AAI59813
ID   AAI59813 standard; cDNA; 1205 BP.
XX
AC   AAI59813;
XX
DT   22-OCT-2001  (first entry)
XX
DE   Human polynucleotide SEQ ID NO 3802.
XX
KW   Human; nootropic; immunosuppressant; cytostatic; gene therapy; cancer;
KW   peripheral nervous system; neuropathy; central nervous system; CNS;
KW   Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
KW   amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;
KW   chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
KW   leukaemia; ss.
XX
OS   Homo sapiens.
XX
PN   WO200153312-A1.
XX
PD   26-JUL-2001.
XX
PF   26-DEC-2000; 2000WO-US34263.
XX
PR   21-JAN-2000; 2000US-0488725.
PR   25-APR-2000; 2000US-0552317.
PR   09-JUL-2000; 2000US-0598042.
PR   19-JUL-2000; 2000US-0620312.
PR   03-AUG-2000; 2000US-0653450.
PR   14-SEP-2000; 2000US-0662191.
PR   19-OCT-2000; 2000US-0693036.
PR   29-NOV-2000; 2000US-0727344.
XX
PA   (HYSE-) HYSEQ INC.
XX
PI   Tang YT,  Liu C,  Asundi V,  Chen R,  Ma Y,  Qian XB,  Ren F,  Wang D;
PI   Wang J,  Wang Z,  Wehrman T,  Xu C,  Xue AJ,  Yang Y,  Zhang J;
PI   Zhao QA,  Zhou P,  Goodrich R,  Drmanac RT;
XX
DR   WPI; 2001-442253/47.
DR   P-PSDB; AAM40657.
XX
PT   Novel nucleic acids and polypeptides, useful for treating disorders
PT   such as central nervous system injuries -
XX
PS   Claim 1; SEQ ID NO 3802; 10078pp; English.
```

```
XX
CC   The invention relates to human nucleic acids (AAI57798-AAI61369) and
CC   the encoded polypeptides (AAM38642-AAM42213) with nootropic,
CC   immunosuppressant and cytostatic activity. The polynucleotides are useful
CC   in gene therapy. A composition containing a polypeptide or polynucleotide
CC   of the invention may be used to treat diseases of the peripheral nervous
CC   system, such as peripheral nervous injuries, peripheral neuropathy and
CC   localised neuropathies and central nervous system diseases, such as
CC   Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
CC   lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
CC   utilisation of the activities such as: Immune system suppression,
CC   Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
CC   and thrombolytic activity, cancer diagnosis and therapy, drug screening,
CC   assays for receptor activity, arthritis and inflammation, leukaemias and
CC   C.N.S disorders.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification.
XX
SQ   Sequence 1205 BP; 324 A; 321 C; 289 G; 271 T; 0 other;


  Query Match             99.6%;  Score 1067.2;  DB 22;  Length 1205;
  Best Local Similarity   99.7%;  Pred. No. 3.1e-280;
  Matches 1069;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1 GACGCCGCCACCTCCGGAACAAGCCATGGTGGCGGCGACGGTGGCAGCGGCGTGGCTGCT 60
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       2 gacgccgccacctccggaacaagccatggtggcggcgacggtggcagcggcgtggctgct 61

Qy      61 CCTGTGGGCTGCGGCCTGCGCGCAGCAGGAGCAGGACTTCTACGACTTCAAGGCGGTCAA 120
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      62 cctgtgggctgcggcctgcgcgcagcaggagcaggacttctacgacttcaaggcggtcaa 121

Qy     121 CATCCGGGGCAAACTGGTGTCGCTGGAGAAGTACCGCGGATCGGTGTCCCTGGTGGTGAA 180
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     122 catccggggcaaactggtgtcgctggagaagtaccgcggatcggtgtccctggtggtgaa 181

Qy     181 TGTGGCCAGCGAGTGCGGCTTCACAGACCAGCACTACCGAGCCCTGCAGCAGCTGCAGCG 240
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     182 tgtggccagcgagtgcggcttcacagaccagcactaccgagccctgcagcagctgcagcg 241

Qy     241 AGACCTGGGCCCCCACCACTTCAACGTGCTCGCCTTCCCCTGCAACCAGTTTGGCCAACA 300
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     242 agacctgggcccccaccacttcaacgtgctcgccttcccctgcaaccagtttggccaaca 301

Qy     301 GGAGCCTGACAGCAACAAGGAGATTGAGAGCTTTGCCTGCCGCACCTACAGTGTCTCATT 360
           |||||||||||||||||||||||||||||||| ||||||||||||||||||||||||||
Db     302 ggagcctgacagcaacaaggagattgagagctttgcccgccgcacctacagtgtctcatt 361

Qy     361 CCCCATGTTTAGCAAGATTGCAGTCACCGGTACTGGTGCCCATCCTGCCTTCAAGTACCT 420
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     362 ccccatgtttagcaagattgcagtcaccggtactggtgcccatcctgccttcaagtacct 421

Qy     421 GGCCCAGACTTCTGGGAAGGAGCCCACCTGGAACTTCTGGAAGTACCTAGTAGCCCCAGA 480
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     422 ggcccagacttctgggaaggagcccacctggaacttctggaagtacctagtagccccaga 481

Qy     481 TGGAAAGGTGGTAGGGGCTTGGGACCCAACTGTGTCAGTGGAGGAGGTCAGACTCCAGAT 540
           |||||||||||||||||||||||||||||||||||||||||||||||||| ||||||
Db     482 tggaaaggtggtaggggcttgggacccaactgtgtcagtggaggaggtcagaccccagat 541

Qy     541 CACAGCGCTCGTGAGGAAGCTCATCCTACTGAAGCGAGAAGACTTATAACCACCGCGTCT 600
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     542 cacagcgctcgtgaggaagctcatcctactgaagcgagaagacttataaccaccgcgtct 601

Qy     601 CCTCCTCCACCACCTCATCCCGCCCACCTGTGTGGGGCTGACCAATGCAAACTCAAATGG 660
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     602 cctcctccaccacctcatcccgcccacctgtgtggggctgaccaatgcaaactcaaatgg 661

Qy     661 TGCTTCAAAGGGAGAGACCCACTGACTCTCCTTCCTTTACTCTTATGCCATTGGTCCCAT 720
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     662 tgcttcaaagggagagacccactgactctccttcctttactcttatgccattggtcccat 721

Qy     721 CATTCTTGTGGGGGAAAAATTCTAGTATTTTGATTATTTGAATCTTACAGCAACAAATAG 780
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     722 cattcttgtgggggaaaaattctagtattttgattatttgaatcttacagcaacaaatag 781

Qy     781 GAACTCCTGGCCAATGAGAGCTCTTGACCAGTGAATCACCAGCCGATACGAACGTCTTGC 840
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     782 gaactcctggccaatgagagctcttgaccagtgaatcaccagccgatacgaacgtcttgc 841

Qy     841 CAACAAAAATGTGTGGCAAATAGAAGTATATCAAGCAATAATCTCCCACCCAAGGCTTCT 900
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     842 caacaaaaatgtgtggcaaatagaagtatatcaagcaataatctcccacccaaggcttct 901

Qy     901 GTAAACTGGGACCAATGATTACCTCATAGGGCTGTTGTGAGGATTAGGATGAAATACCTG 960
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     902 gtaaactgggaccaatgattacctcatagggctgttgtgaggattaggatgaaatacctg 961

Qy     961 TGAAAGTGCCTAGGCAGTGCCAGCCAAATAGGAGGCATTCAATGAACATTTTTTGCATAT 1020
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     962 tgaaagtgcctaggcagtgccagccaaataggaggcattcaatgaacatttttgcatat 1021

Qy    1021 AAACCAAAAAATAACTTGTTATCAATAAAAACTTGCATCCAACATGAATTTC 1072
           ||| ||||||||||||||||||||||||||||||||||||||||||||||||
Db    1022 aaaacaaaaaataacttgttatcaataaaaacttgcatccaacatgaatttc 1073


RESULT   4
AAH14527
ID   AAH14527 standard; cDNA; 1228 BP.
XX
AC   AAH14527;
XX
DT   26-JUN-2001  (first entry)
XX
DE   Human cDNA sequence SEQ ID NO:12070.
XX
KW   Human; primer; detection; diagnosis; antisense therapy; gene therapy; ss.
XX
OS   Homo sapiens.
XX
PN   EP1074617-A2.
XX
PD   07-FEB-2001.
XX
PF   28-JUL-2000; 2000EP-0116126.
XX
PR   29-JUL-1999;   99JP-0248036.
PR   27-AUG-1999;   99JP-0300253.
PR   11-JAN-2000; 2000JP-0118776.
PR   02-MAY-2000; 2000JP-0183767.
PR   09-JUN-2000; 2000JP-0241899.
XX
PA   (HELI-) HELIX RES INST.
XX
PI   Ota T,  Isogai T,  Nishikawa T,  Hayashi K,  Saito K,  Yamamoto J;
PI   Ishii S,  Sugiyama T,  Wakamatsu A,  Nagai K,  Otsuki T;
XX
DR   WPI; 2001-318749/34.
XX
PT   Primer sets for synthesizing polynucleotides, particularly the 5602
PT   full-length cDNAs defined in the specification, and for the detection
PT   and/or diagnosis of the abnormality of the proteins encoded by the
PT   full-length cDNAs -
XX
PS   Claim 8; SEQ ID 12070; 2537pp + CD ROM; English.
XX
CC   The present invention describes primer sets for synthesising 5602
CC   full-length cDNAs defined in the specification. Where a primer set
CC   comprises: (a) an oligo-dT primer and an oligonucleotide complementary
CC   to the complementary strand of a polynucleotide which comprises one of
CC   the 5602 nucleotide sequences defined in the specification, where the
CC   oligonucleotide comprises at least 15 nucleotides; or (b) a combination
CC   of an oligonucleotide comprising a sequence complementary to the
CC   complementary strand of a polynucleotide which comprises a 5'-end
```

```
CC   sequence and an oligonucleotide comprising a sequence complementary to a
CC   polynucleotide which comprises a 3'-end sequence, where the
CC   oligonucleotide comprises at least 15 nucleotides and the combination of
CC   the 5'-end sequence/3'-end sequence is selected from those defined in
CC   the specification. The primer sets can be used in antisense therapy and
CC   in gene therapy. The primers are useful for synthesising polynucleotides,
CC   particularly full-length cDNAs. The primers are also useful for the
CC   detection and/or diagnosis of the abnormality of the proteins encoded by
CC   the full-length cDNAs. The primers allow obtaining of the full-length
CC   cDNAs easily without any specialised methods. AAH03166 to AAH13628 and
CC   AAH13633 to AAH18742 represent human cDNA sequences; AAB92446 to
CC   AAB95893 represent human amino acid sequences; and AAH13629 to AAH13632
CC   represent oligonucleotides, all of which are used in the exemplification
CC   of the present invention.
XX
SQ   Sequence 1228 BP; 326 A; 330 C; 290 G; 282 T; 0 other;


  Query Match             99.6%;  Score 1067.2;  DB 22;  Length 1228;
  Best Local Similarity   99.7%;  Pred. No. 3.2e-280;
  Matches 1069;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1 GACGCCGCCACCTCCGGAACAAGCCATGGTGGCGGCGACGGTGGCAGCGGCGTGGCTGCT 60
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      15 gacgccgccacctccggaacaagccatggtggcggcgacggtggcagcggcgtggctgct 74

Qy      61 CCTGTGGGCTGCGGCCTGCGCGCAGCAGGAGCAGGACTTCTACGACTTCAAGGCGGTCAA 120
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      75 cctgtgggctgcggcctgcgcgcagcaggagcaggacttctacgacttcaaggcggtcaa 134

Qy     121 CATCCGGGGCAAACTGGTGTCGCTGGAGAAGTACCGCGGATCGGTGTCCCTGGTGGTGAA 180
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     135 catccggggcaaactggtgtcgctggagaagtaccgcggatcggtgtccctggtggtgaa 194

Qy     181 TGTGGCCAGCGAGTGCGGCTTCACAGACCAGCACTACCGAGCCCTGCAGCAGCTGCAGCG 240
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     195 tgtggccagcgagtgcggcttcacagaccagcactaccgagccctgcagcagctgcagcg 254

Qy     241 AGACCTGGGCCCCCACCACTTCAACGTGCTCGCCTTCCCCTGCAACCAGTTTGGCCAACA 300
          |||||||||||||||||| ||||||||||||||||||||||||||||||||||||||||
Db     255 agacctgggccccaccactttaacgtgctcgccttccccctgcaaccagtttggccaaca 314

Qy     301 GGAGCCTGACAGCAACAAGGAGATTGAGAGCTTTGCCTGCCGCACCTACAGTGTCTCATT 360
          |||||||||||||||||||||||||||||||| ||||||||||||||||||||||||||||
Db     315 ggagcctgacagcaacaaggagattgagagctttgcccgccgcacctacagtgtctcatt 374

Qy     361 CCCCATGTTTAGCAAGATTGCAGTCACCGGTACTGGTGCCCATCCTGCCTTCAAGTACCT 420
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     375 ccccatgtttagcaagattgcagtcaccggtactggtgcccatcctgccttcaagtacct 434

Qy     421 GGCCCAGACTTCTGGGAAGGAGCCCACCTGGAACTTCTGGAAGTACCTAGTAGCCCCAGA 480
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     435 ggcccagacttctgggaaggagcccacctggaacttctggaagtacctagtagccccaga 494

Qy     481 TGGAAAGGTGGTAGGGGCTTGGGACCCAACTGTGTCAGTGGAGGAGGTCAGACTCCAGAT 540
          |||||||||||||||||||||||||||||||||||||||||||||||||||||| ||||||
Db     495 tggaaaggtggtaggggcttgggacccaactgtgtcagtggaggaggtcagaccccagat 554

Qy     541 CACAGCGCTCGTGAGGAAGCTCATCCTACTGAAGCGAGAAGACTTATAACCACCGCGTCT 600
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     555 cacagcgctcgtgaggaagctcatcctactgaagcgagaagacttataaccaccgcgtct 614

Qy     601 CCTCCTCCACCACCTCATCCCGCCCACCTGTGTGGGGCTGACCAATGCAAACTCAAATGG 660
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     615 cctcctccaccacctcatcccgcccacctgtgtggggctgaccaatgcaaactcaaatgg 674

Qy     661 TGCTTCAAAGGGAGAGACCCACTGACTCTCCTTCCTTTACTCTTATGCCATTGGTCCCAT 720
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     675 tgcttcaaagggagagacccactgactctccttcctttactcttatgccattggtcccat 734

Qy     721 CATTCTTGTGGGGGAAAAATTCTAGTATTTTGATTATTTGAATCTTACAGCAACAAATAG 780
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     735 cattcttgtgggggaaaaattctagtattttgattatttgaatcttacagcaacaaatag 794

Qy     781 GAACTCCTGGCCAATGAGAGCTCTTGACCAGTGAATCACCAGCCGATACGAACGTCTTGC 840
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     795 gaactcctggccaatgagagctcttgaccagtgaatcaccagccgatacgaacgtcttgc 854

Qy     841 CAACAAAAATGTGTGGCAAATAGAAGTATATCAAGCAATAATCTCCCACCCAAGGCTTCT 900
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     855 caacaaaaatgtgtggcaaatagaagtatatcaagcaataatctcccacccaaggcttct 914

Qy     901 GTAAACTGGGACCAATGATTACCTCATAGGGCTGTTGTGAGGATTAGGATGAAATACCTG 960
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     915 gtaaactgggaccaatgattacctcatagggctgttgtgaggattaggatgaaatacctg 974

Qy     961 TGAAAGTGCCTAGGCAGTGCCAGCCAAATAGGAGGCATTCAATGAACATTTTTTGCATAT 1020
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     975 tgaaagtgcctaggcagtgccagccaaataggaggcattcaatgaacatttttttgcatat 1034

Qy    1021 AAACCAAAAAAATAACTTGTTATCAATAAAAACTTGCATCCAACATGAATTTC 1072
          ||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1035 aaaccaaaaaaataacttgttatcaataaaaacttgcatccaacatgaatttc 1086


RESULT   5
AAH72778
ID   AAH72778 standard; cDNA; 1511 BP.
XX
AC   AAH72778;
XX
DT   19-SEP-2001  (first entry)
XX
DE   Human cervical cancer marker nucleic acid 4052.
XX
KW   Cervical cancer; cytostatic; pre-malignant condition; gene therapy; ss.
XX
OS   Homo sapiens.
XX
PN   WO200142467-A2.
XX
PD   14-JUN-2001.
XX
PF   08-DEC-2000; 2000WO-US33312.
XX
PR   08-DEC-1999;   99US-0169681.
PR   21-DEC-1999;   99US-0171350.
PR   14-MAR-2000; 2000US-0189315.
PR   12-MAY-2000; 2000US-0203791.
PR   09-JUN-2000; 2000US-0210600.
PR   21-JUL-2000; 2000US-0220114.
XX
PA   (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.
XX
PI   Schlegel R,  Deeds J,  Berger A,  Zhao X;
XX
DR   WPI; 2001-375006/39.
XX
PT   New isolated nucleic acid for diagnosing and treating cervical cancer
PT   and for assessing and detecting compounds for treating the cancer -
XX
PS   Claim 1; Page 845-847; 1051pp; English.
XX
CC   The invention relates to novel genes (AAH68727-AAH73383) associated with
CC   cervical cancer with cytostatic activity. The nucleic acids and encoded
CC   polypeptides are useful: to assess if a patient is afflicted with
CC   cervical cancer or has a pre-malignant condition; to monitor the
CC   progression of cervical cancer or a premalignant condition in a patient;
CC   and to select and/or assess the efficacy of a compound or therapy for
CC   inhibiting cervical cancer in a patient. The nucleic acids may also be
CC   useful for gene therapy.
XX
SQ   Sequence 1511 BP; 392 A; 421 C; 378 G; 314 T; 6 other;


  Query Match             99.6%;  Score 1067.2;  DB 22;  Length 1511;
```

```
  Best Local Similarity   99.7%;  Pred. No. 3.5e-280;
  Matches 1069;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1 GACGCCGCCACCTCCGGAACAAGCCATGGTGGCGGCGACGGTGGCAGCGGCGTGGCTGCT 60
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     276 gacgccgccacctccggaacaagccatggtggcggcgacggtggcagcggcgtggctgct 335

Qy      61 CCTGTGGGCTGCGGCCTGCGCGCAGCAGGAGCAGGACTTCTACGACTTCAAGGCGGTCAA 120
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     336 cctgtgggctgcggcctgcgcgcagcaggagcaggacttctacgacttcaaggcggtcaa 395

Qy     121 CATCCGGGGCAAACTGGTGTCGCTGGAGAAGTACCGCGGATCGGTGTCCCTGGTGGTGAA 180
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     396 catccggggcaaactggtgtcgctggagaagtaccgcggatcggtgtccctggtggtgaa 455

Qy     181 TGTGGCCAGCGAGTGCGGCTTCACAGACCAGCACTACCGAGCCCTGCAGCAGCTGCAGCG 240
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     456 tgtggccagcgagtgcggcttcacagaccagcactaccgagccctgcagcagctgcagcg 515

Qy     241 AGACCTGGGCCCCCACCACTTCAACGTGCTCGCCTTCCCCTGCAACCAGTTTGGCCAACA 300
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     516 agacctgggcccccaccacttcaacgtgctcgccttcccctgcaaccagtttggccaaca 575

Qy     301 GGAGCCTGACAGCAACAAGGAGATTGAGAGCTTTGCCTGCCGCACCTACAGTGTCTCATT 360
           ||||||||||||||||||||||||||||||||| ||||||||||||||||||||||||||
Db     576 ggagcctgacagcaacaaggagattgagagctttgcccgccgcacctacagtgtctcatt 635

Qy     361 CCCCATGTTTAGCAAGATTGCAGTCACCGGTACTGGTGCCCATCCTGCCTTCAAGTACCT 420
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     636 ccccatgtttagcaagattgcagtcaccggtactggtgcccatcctgccttcaagtacct 695

Qy     421 GGCCCAGACTTCTGGGAAGGAGCCCACCTGGAACTTCTGGAAGTACCTAGTAGCCCCAGA 480
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     696 ggcccagacttctgggaaggagcccacctggaacttctggaagtacctagtagccccaga 755

Qy     481 TGGAAAGGTGGTAGGGGCTTGGGACCCAACTGTGTCAGTGGAGGAGGTCAGACTCCAGAT 540
           |||||||||||||||||||||||||||||||||||||||||||||||||||| ||||||
Db     756 tggaaaggtggtaggggcttgggacccaactgtgtcagtggaggaggtcagaccccagat 815

Qy     541 CACAGCGCTCGTGAGGAAGCTCATCCTACTGAAGCGAGAAGACTTATAACCACCGCGTCT 600
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     816 cacagcgctcgtgaggaagctcatcctactgaagcgagaagacttataaccaccgcgtct 875

Qy     601 CCTCCTCCACCACCTCATCCCGCCCACCTGTGTGGGGCTGACCAATGCAAACTCAAATGG 660
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     876 cctcctccaccacctcatcccgcccacctgtgtggggctgaccaatgcaaactcaaatgg 935

Qy     661 TGCTTCAAAGGGAGAGACCCACTGACTCTCCTTCCTTTACTCTTATGCCATTGGTCCCAT 720
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     936 tgcttcaaagggagagacccactgactctccttccttactcttatgccattggtcccat 995

Qy     721 CATTCTTGTGGGGGAAAAATTCTAGTATTTTGATTATTTGAATCTTACAGCAACAAATAG 780
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     996 cattcttgtgggggaaaaattctagtattttgattatttgaatcttacagcaacaaatag 1055

Qy     781 GAACTCCTGGCCAATGAGAGCTCTTGACCAGTGAATCACCAGCCGATACGAACGTCTTGC 840
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1056 gaactcctggccaatgagagctcttgaccagtgaatcaccagccgatacgaacgtcttgc 1115

Qy     841 CAACAAAAATGTGTGGCAAATAGAAGTATATCAAGCAATAATCTCCCACCCAAGGCTTCT 900
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1116 caacaaaaatgtgtggcaaatagaagtatatcaagcaataatctcccacccaaggcttct 1175

Qy     901 GTAAACTGGGACCAATGATTACCTCATAGGGCTGTTGTGAGGATTAGGATGAAATACCTG 960
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1176 gtaaactgggaccaatgattacctcatagggctgttgtgaggattaggatgaaatacctg 1235

Qy     961 TGAAAGTGCCTAGGCAGTGCCAGCCAAATAGGAGGCATTCAATGAACATTTTTTGCATAT 1020
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1236 tgaaagtgcctaggcagtgccagccaaataggaggcattcaatgaacatttttttgcatat 1295

Qy    1021 AAACCAAAAAAATAACTTGTTATCAATAAAAACTTGCATCCAACATGAATTTC 1072
           ||| ||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1296 aaaacaaaaaataacttgttatcaataaaaacttgcatccaacatgaatttc 1347
```

RESULT 6
AAF81788
ID AAF81788 standard; cDNA; 1315 BP.
XX
AC AAF81788;
XX
DT 12-JUN-2001 (first entry)
XX
DE Human secreted protein gene 2 SEQ ID NO:12.
XX
KW Human; secreted protein; diagnosis; immunomodulatory; antisclerotic;
KW dermatological; immunosuppressive; antiinflammatory; anti-HIV;
KW immunostimulant; cytostatic; cardiant; vascular; anti-angiogenic;
KW ophthalmological; neuroprotectant; nootropic; anticonvulsant; vaccine;
KW antialzheimer; antiparkinsonian; antimicrobial; vulnerary; gene therapy;
KW immune disorder; hyperproliferative disorder; cardiovascular disease;
KW cancer; angiogenic disorder; neurological disorder; infectious disease;
KW wound healing; regeneration; chemotaxis; ss.
XX
OS Homo sapiens.
XX
PN WO200112775-A2.
XX
PD 22-FEB-2001.
XX
PF 16-AUG-2000; 2000WO-US22325.
XX
PR 17-AUG-1999; 99US-0149182.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Ni J, Florence KA, Fiscella M, Wei P, Baker KP;
PI Birse CE, Young PE, Komatsoulis GA, Moore PA, Soppet DR;
XX
DR WPI; 2001-147550/15.
DR P-PSDB; AAB74734.
XX
PT Nucleic acids encoding 25 human secreted polypeptides, useful for
PT preventing, diagnosing and/or treating e.g. cancers, Parkinson's
PT disease and diabetic retinopathy -
XX
PS Claim 1; Page 441-442; 485pp; English.
XX
CC AAF81787 to AAF81817 encode the human secreted proteins given in AAB74733
CC to AAB74772. Human secreted proteins can have activities based on the
CC tissues and cells they are expressed in. Example of activities include:
CC immunomodulatory; antisclerotic; dermatological; immunosuppressive;
CC antiinflammatory; anti-HIV; immunostimulant; cytostatic; cardiant;
CC vascular; anti-angiogenic; ophthalmological; neuroprotectant; nootropic;
CC anticonvulsant; antialzheimers; antiparkinsonian; antimicrobial; and
CC vulnerary. Human secreted proteins can be used in gene therapy and
CC vaccine. Human secreted protein nucleotide sequences (NAM1) and proteins
CC (PEP1) may be used in the prevention, diagnosis and treatment of diseases
CC associated with inappropriate polypeptide expression. For example, NAM1
CC and PEP1 may be used to treat disorders associated with decreased
CC expression by rectifying mutations or deletions in a patients genome
CC that affect the activity of proteins by expressing inactive proteins or
CC to supplement the patients own production of polypeptides. Disorders that
CC may be prevented, diagnosed and/or treated include immune disorders,
CC hyperproliferative disorders (e.g. cancers), cardiovascular diseases,
CC angiogenic disorders, neurological disorders, infectious diseases and/or
CC for promoting wound healing, regeneration and /or chemotaxis. AAF81778 to
CC AAF81786 and AAB74732 represent sequences used in the exemplification of
CC the present invention.
XX
SQ Sequence 1315 BP; 419 A; 329 C; 290 G; 277 T; 0 other;

```
  Query Match           99.4%;  Score 1065.6;  DB 22;  Length 1315;
  Best Local Similarity 99.6%;  Pred. No. 8.9e-280;
```

```
  Matches 1068;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1 GACGCCGCCACCTCCGGAACAAGCCATGGTGGCGGCGACGGTGGCAGCGGCGTGGCTGCT 60
          ||||||||||||||||||||||||||||||||| ||||||||||||||||||||||||||
Db      10 gacgccgccacctccggaacaagccatggtggcggctacggtggcagcggcgtggctgct 69

Qy      61 CCTGTGGGCTGCGGCCTGCGCGCAGCAGGAGCAGGACTTCTACGACTTCAAGGCGGTCAA 120
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      70 cctgtgggctgcggcctgcgcgcagcaggagcaggacttctacgacttcaaggcggtcaa 129

Qy     121 CATCCGGGGCAAACTGGTGTCGCTGGAGAAGTACCGCGGATCGGTGTCCCTGGTGGTGAA 180
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     130 catccggggcaaactggtgtcgctggagaagtaccgcggatcggtgtccctggtggtgaa 189

Qy     181 TGTGGCCAGCGAGTGCGGCTTCACAGACCAGCACTACCGAGCCCTGCAGCAGCTGCAGCG 240
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     190 tgtggccagcgagtgcggcttcacagaccagcactaccgagccctgcagcagctgcagcg 249

Qy     241 AGACCTGGGCCCCCACCACTTCAACGTGCTCGCCTTCCCCTGCAACCAGTTTGGCCAACA 300
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     250 agacctgggcccccaccacttcaacgtgctcgccttcccctgcaaccagtttggccaaca 309

Qy     301 GGAGCCTGACAGCAACAAGGAGATTGAGAGCTTTGCCTGCCGCACCTACAGTGTCTCATT 360
          |||||||||||||||||||||||||||||||| ||||||||||||||||||||||||||
Db     310 ggagcctgacagcaacaaggagattgagagctttgcccgccgcacctacagtgtctcatt 369

Qy     361 CCCCATGTTTAGCAAGATTGCAGTCACCGGTACTGGTGCCCATCCTGCCTTCAAGTACCT 420
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     370 ccccatgtttagcaagattgcagtcaccggtactggtgcccatcctgccttcaagtacct 429

Qy     421 GGCCCAGACTTCTGGGAAGGAGCCCACCTGGAACTTCTGGAAGTACCTAGTAGCCCCAGA 480
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     430 ggcccagacttctgggaaggagcccacctggaacttctggaagtacctagtagccccaga 489

Qy     481 TGGAAAGGTGGTAGGGGCTTGGGACCCAACTGTGTCAGTGGAGGAGGTCAGACTCCAGAT 540
          |||||||||||||||||||||||||||||||||||||||||||||||| ||||||
Db     490 tggaaaggtggtaggggcttgggacccaactgtgtcagtggaggaggtcagaccccagat 549

Qy     541 CACAGCGCTCGTGAGGAAGCTCATCCTACTGAAGCGAGAAGACTTATAACCACCGCGTCT 600
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     550 cacagcgctcgtgaggaagctcatcctactgaagcgagaagacttataaccaccgcgtct 609

Qy     601 CCTCCTCCACCACCTCATCCCGCCCACCTGTGTGGGGCTGACCAATGCAAACTCAAATGG 660
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     610 cctcctccaccacctcatcccgcccacctgtgtggggctgaccaatgcaaactcaaatgg 669

Qy     661 TGCTTCAAAGGGAGAGACCCACTGACTCTCCTTCCTTTACTCTTATGCCATTGGTCCCAT 720
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     670 tgcttcaaagggagagacccactgactctccttcctttactcttatgccattggtcccat 729

Qy     721 CATTCTTGTGGGGGAAAAATTCTAGTATTTTGATTATTTGAATCTTACAGCAACAAATAG 780
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     730 cattcttgtgggggaaaaattctagtattttgattatttgaatcttacagcaacaaatag 789

Qy     781 GAACTCCTGGCCAATGAGAGCTCTTGACCAGTGAATCACCAGCCGATACGAACGTCTTGC 840
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     790 gaactcctggccaatgagagctcttgaccagtgaatcaccagccgatacgaacgtcttgc 849

Qy     841 CAACAAAAATGTGTGGCAAATAGAAGTATATCAAGCAATAATCTCCCACCCAAGGCTTCT 900
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     850 caacaaaaatgtgtggcaaatagaagtatatcaagcaataatctcccacccaaggcttct 909

Qy     901 GTAAACTGGGACCAATGATTACCTCATAGGGCTGTTGTGAGGATTAGGATGAAATACCTG 960
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     910 gtaaactgggaccaatgattacctcatagggctgttgtgaggattaggatgaaatacctg 969

Qy     961 TGAAAGTGCCTAGGCAGTGCCAGCCAAATAGGAGGCATTCAATGAACATTTTTTGCATAT 1020
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||||| ||
Db     970 tgaaagtgcctaggcagtgccagccaaataggaggcattcaatgaacatttttgcacat 1029

Qy    1021 AAACCAAAAAATAACTTGTTATCAATAAAAACTTGCATCCAACATGAATTTC 1072
          ||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1030 aaaccaaaaaataacttgttatcaataaaaacttgcatccaacatgaatttc 1081
```

```
RESULT   7
AAZ65013
ID   AAZ65013 standard; cDNA; 1227 BP.
XX
AC   AAZ65013;
XX
DT   05-APR-2000  (first entry)
XX
DE   Membrane-bound protein PRO828 encoding cDNA.
XX
KW   Membrane-bound polypeptide; PRO polypeptide; LDL receptor; TIE ligand;
KW   pharmaceutical; receptor immunoadhesin; gene mapping; ss.
XX
OS   Homo sapiens.
XX
PN   WO9963088-A2.
XX
PD   09-DEC-1999.
XX
PF   02-JUN-1999;   99WO-US12252.
XX
PR   02-JUN-1998;   98US-0087607.
PR   02-JUN-1998;   98US-0087609.
PR   02-JUN-1998;   98US-0087759.
PR   03-JUN-1998;   98US-0087827.
PR   04-JUN-1998;   98US-0088021.
PR   04-JUN-1998;   98US-0088025.
PR   04-JUN-1998;   98US-0088028.
PR   04-JUN-1998;   98US-0088029.
PR   04-JUN-1998;   98US-0088030.
PR   04-JUN-1998;   98US-0088033.
PR   04-JUN-1998;   98US-0088326.
PR   05-JUN-1998;   98US-0088167.
PR   05-JUN-1998;   98US-0088202.
PR   05-JUN-1998;   98US-0088212.
PR   05-JUN-1998;   98US-0088217.
PR   09-JUN-1998;   98US-0088655.
PR   10-JUN-1998;   98US-0088722.
PR   10-JUN-1998;   98US-0088730.
PR   10-JUN-1998;   98US-0088734.
PR   10-JUN-1998;   98US-0088738.
PR   10-JUN-1998;   98US-0088740.
PR   10-JUN-1998;   98US-0088741.
PR   10-JUN-1998;   98US-0088742.
PR   10-JUN-1998;   98US-0088810.
PR   10-JUN-1998;   98US-0088811.
PR   10-JUN-1998;   98US-0088824.
PR   10-JUN-1998;   98US-0088825.
PR   10-JUN-1998;   98US-0088826.
PR   11-JUN-1998;   98US-0088858.
PR   11-JUN-1998;   98US-0088861.
PR   11-JUN-1998;   98US-0088863.
PR   11-JUN-1998;   98US-0088876.
PR   12-JUN-1998;   98US-0089090.
PR   12-JUN-1998;   98US-0089105.
PR   16-JUN-1998;   98US-0089440.
PR   16-JUN-1998;   98US-0089512.
PR   16-JUN-1998;   98US-0089514.
PR   17-JUN-1998;   98US-0089532.
PR   17-JUN-1998;   98US-0089538.
PR   17-JUN-1998;   98US-0089598.
PR   17-JUN-1998;   98US-0089599.
PR   17-JUN-1998;   98US-0089600.
PR   17-JUN-1998;   98US-0089653.
PR   18-JUN-1998;   98US-0089801.
PR   18-JUN-1998;   98US-0089907.
PR   18-JUN-1998;   98US-0089908.
PR   19-JUN-1998;   98US-0089947.
PR   19-JUN-1998;   98US-0089948.
PR   19-JUN-1998;   98US-0089952.
PR   22-JUN-1998;   98US-0090246.
```

PR 22-JUN-1998; 98US-0090252.
PR 22-JUN-1998; 98US-0090254.
PR 23-JUN-1998; 98US-0090349.
PR 23-JUN-1998; 98US-0090355.
PR 24-JUN-1998; 98US-0090429.
PR 24-JUN-1998; 98US-0090431.
PR 24-JUN-1998; 98US-0090435.
PR 24-JUN-1998; 98US-0090444.
PR 24-JUN-1998; 98US-0090445.
PR 24-JUN-1998; 98US-0090461.
PR 24-JUN-1998; 98US-0090472.
PR 24-JUN-1998; 98US-0090535.
PR 24-JUN-1998; 98US-0090538.
PR 24-JUN-1998; 98US-0090540.
PR 24-JUN-1998; 98US-0090557.
PR 25-JUN-1998; 98US-0090676.
PR 25-JUN-1998; 98US-0090678.
PR 25-JUN-1998; 98US-0090688.
PR 25-JUN-1998; 98US-0090690.
PR 25-JUN-1998; 98US-0090691.
PR 25-JUN-1998; 98US-0090694.
PR 25-JUN-1998; 98US-0090695.
PR 25-JUN-1998; 98US-0090696.
PR 26-JUN-1998; 98US-0090862.
PR 26-JUN-1998; 98US-0090863.
PR 01-JUL-1998; 98US-0091358.
PR 01-JUL-1998; 98US-0091360.
PR 01-JUL-1998; 98US-0091544.
PR 02-JUL-1998; 98US-0091478.
PR 02-JUL-1998; 98US-0091486.
PR 02-JUL-1998; 98US-0091519.
PR 02-JUL-1998; 98US-0091626.
PR 02-JUL-1998; 98US-0091628.
PR 02-JUL-1998; 98US-0091633.
PR 02-JUL-1998; 98US-0091646.
PR 02-JUL-1998; 98US-0091673.
PR 07-JUL-1998; 98US-0091978.
PR 07-JUL-1998; 98US-0091982.
PR 09-JUL-1998; 98US-0092182.
PR 10-JUL-1998; 98US-0092472.
PR 20-JUL-1998; 98US-0093339.
PR 30-JUL-1998; 98US-0094651.
PR 04-AUG-1998; 98US-0095282.
PR 04-AUG-1998; 98US-0095285.
PR 04-AUG-1998; 98US-0095301.
PR 04-AUG-1998; 98US-0095302.
PR 04-AUG-1998; 98US-0095318.
PR 04-AUG-1998; 98US-0095321.
PR 04-AUG-1998; 98US-0095325.
PR 10-AUG-1998; 98US-0095916.
PR 10-AUG-1998; 98US-0095929.
PR 10-AUG-1998; 98US-0096012.
PR 11-AUG-1998; 98US-0096143.
PR 11-AUG-1998; 98US-0096146.
PR 12-AUG-1998; 98US-0096329.
PR 17-AUG-1998; 98US-0096757.
PR 17-AUG-1998; 98US-0096766.
PR 17-AUG-1998; 98US-0096768.
PR 17-AUG-1998; 98US-0096773.
PR 17-AUG-1998; 98US-0096791.
PR 17-AUG-1998; 98US-0096867.
PR 17-AUG-1998; 98US-0096891.
PR 17-AUG-1998; 98US-0096894.
PR 17-AUG-1998; 98US-0096895.
PR 17-AUG-1998; 98US-0096897.
PR 18-AUG-1998; 98US-0096949.
PR 18-AUG-1998; 98US-0096950.
PR 18-AUG-1998; 98US-0096959.
PR 18-AUG-1998; 98US-0096960.
PR 18-AUG-1998; 98US-0097022.
PR 19-AUG-1998; 98US-0097141.
PR 20-AUG-1998; 98US-0097218.
PR 24-AUG-1998; 98US-0097661.
PR 26-AUG-1998; 98US-0097951.
PR 26-AUG-1998; 98US-0097952.
PR 26-AUG-1998; 98US-0097954.
PR 26-AUG-1998; 98US-0097955.
PR 26-AUG-1998; 98US-0097971.
PR 26-AUG-1998; 98US-0097974.
PR 26-AUG-1998; 98US-0097978.
PR 26-AUG-1998; 98US-0097979.
PR 26-AUG-1998; 98US-0097986.
PR 26-AUG-1998; 98US-0098014.
PR 31-AUG-1998; 98US-0098525.
PR 16-SEP-1998; 98US-0100634.
PR 12-JAN-1999; 99US-0115565.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker K, Chen J, Goddard A, Gurney AL, Smith V, Watanabe CK;
PI Wood WI, Yuan J;
XX
DR WPI; 2000-072883/06.
DR P-PSDB; AAY66677.
XX
PT Membrane-bound proteins and related nucleotide sequences -
XX
PS Claim 2; Fig 119; 822pp; English.
XX
CC The invention provides membrane-bound PRO polypeptides and
CC polynucleotides encoding them. The PRO sequences of the invention were
CC identified based on extracellular domain homology screening. The PRO
CC sequences have homology with proteins including LDL receptors, TIE
CC ligands and various enzymes. The membrane-bound proteins and receptor
CC molecules are useful as pharmaceutical and diagnostic agents. Receptor
CC immunoadhesins, for instance, can be used as therapeutic agents to block
CC receptor-ligand interactions. The membrane-bound proteins can also be
CC employed for screening of potential peptide or small molecule inhibitors
CC of the relevant receptor/ligand interaction. The PRO encoding sequences
CC are useful as hybridization probes, in chromosome and gene mapping and in
CC the generation of antisense RNA and DNA. PRO nucleic acid sequences
CC will also be useful for the preparation of PRO polypeptides, especially
CC by recombinant techniques.
XX
SQ Sequence 1227 BP; 331 A; 325 C; 293 G; 278 T; 0 other;

Query Match 99.3%; Score 1064.2; DB 21; Length 1227;
Best Local Similarity 99.7%; Pred. No. 2.1e-279;
Matches 1066; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       4 GCCGCCACCTCCGGAACAAGCCATGGTGGCGGCGACGGTGGCAGCGGCGTGGCTGCTCCT 63
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      12 gccgccacctccggaacaagccatggtggcggcgacggtggcagcggcgtggctgctcct 71

Qy      64 GTGGGCTGCGGCCTGCGCGCAGCAGGAGCAGGACTTCTACGACTTCAAGGCGGTCAACAT 123
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      72 gtgggctgcggcctgcgcgcagcaggagcaggacttctacgacttcaaggcggtcaacat 131

Qy     124 CCGGGGCAAACTGGTGTCGCTGGAGAAGTACCGCGGATCGGTGTCCCTGGTGGTGAATGT 183
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     132 ccggggcaaactggtgtcgctggagaagtaccgcggatcggtgtccctggtggtgaatgt 191

Qy     184 GGCCAGCGAGTGCGGCTTCACAGACCAGCACTACCGAGCCCTGCAGCAGCTGCAGCGAGA 243
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     192 ggccagcgagtgcggcttcacagaccagcactaccgagccctgcagcagctgcagcgaga 251

Qy     244 CCTGGGCCCCCACCACTTCAACGTGCTCGCCTTCCCCTGCAACCAGTTTGGCCAACAGGA 303
          |||||||||||||||||| ||||||||||||||||||||||||||||||||||||||||||
Db     252 cctgggcccccaccactttaacgtgctcgccttcccctgcaaccagtttggccaacagga 311

Qy     304 GCCTGACAGCAACAAGGAGATTGAGAGCTTTGCCTGCCGCACCTACAGTGTCTCATTCCC 363
          |||||||||||||||||||||||||||||||| ||||||||||||||||||||||||||||
Db     312 gcctgacagcaacaaggagattgagagctttgcccgccgcacctacagtgtctcattccc 371

Qy     364 CATGTTTAGCAAGATTGCAGTCACCGGTACTGGTGCCCATCCTGCCTTCAAGTACCTGGC 423
```

```
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     372 catgtttagcaagattgcagtcaccggtactggtgcccatcctgccttcaagtacctggc 431

Qy     424 CCAGACTTCTGGGAAGGAGCCCACCTGGAACTTCTGGAAGTACCTAGTAGCCCCAGATGG 483
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     432 ccagacttctgggaaggagcccacctggaacttctggaagtacctagtagccccagatgg 491

Qy     484 AAAGGTGGTAGGGGCTTGGGACCCAACTGTGTCAGTGGAGGAGGTCAGACTCCAGATCAC 543
          |||||||||||||||||||||||||||||||||||||||||||||||| |||||||||
Db     492 aaaggtggtaggggcttgggacccaactgtgtcagtggaggaggtcagaccccagatcac 551

Qy     544 AGCGCTCGTGAGGAAGCTCATCCTACTGAAGCGAGAAGACTTATAACCACCGCGTCTCCT 603
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     552 agcgctcgtgaggaagctcatcctactgaagcgagaagacttataaccaccgcgtctcct 611

Qy     604 CCTCCACCACCTCATCCCGCCCACCTGTGTGGGGCTGACCAATGCAAACTCAAATGGTGC 663
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     612 cctccaccacctcatcccgcccacctgtgtggggctgaccaatgcaaactcaaatggtgc 671

Qy     664 TTCAAAGGGAGAGACCCACTGACTCTCCTTCCTTTACTCTTATGCCATTGGTCCCATCAT 723
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     672 ttcaaagggagagacccactgactctccttcctttactcttatgccattggtcccatcat 731

Qy     724 TCTTGTGGGGGAAAAATTCTAGTATTTTGATTATTTGAATCTTACAGCAACAAATAGGAA 783
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     732 tcttgtgggggaaaaattctagtattttgattatttgaatcttacagcaacaaataggaa 791

Qy     784 CTCCTGGCCAATGAGAGCTCTTGACCAGTGAATCACCAGCCGATACGAACGTCTTGCCAA 843
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     792 ctcctggccaatgagagctcttgaccagtgaatcaccagccgatacgaacgtcttgccaa 851

Qy     844 CAAAAATGTGTGGCAAATAGAAGTATATCAAGCAATAATCTCCCACCCAAGGCTTCTGTA 903
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     852 caaaaatgtgtggcaaatagaagtatatcaagcaataatctcccacccaaggcttctgta 911

Qy     904 AACTGGGACCAATGATTACCTCATAGGGCTGTTGTGAGGATTAGGATGAAATACCTGTGA 963
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     912 aactgggaccaatgattacctcatagggctgttgtgaggattaggatgaaatacctgtga 971

Qy     964 AAGTGCCTAGGCAGTGCCAGCCAAATAGGAGGCATTCAATGAACATTTTTTGCATATAAA 1023
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     972 aagtgcctaggcagtgccagccaaataggaggcattcaatgaacatttttttgcatataaa 1031

Qy    1024 CCAAAAAATAACTTGTTATCAATAAAAACTTGCATCCAACATGAATTTC 1072
          ||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1032 ccaaaaaataacttgttatcaataaaaacttgcatccaacatgaatttc 1080


RESULT   8
AAS46137
ID   AAS46137 standard; cDNA; 1227 BP.
XX
AC   AAS46137;
XX
DT   18-DEC-2001  (first entry)
XX
DE   Human DNA encoding PRO polypeptide sequence #213.
XX
KW   PRO polypeptide; mammal; tumour; cancer; human; cattle; horse; sheep; ss;
KW   dog; cat; pig; goat; rabbit; tumour necrosis factor alpha; TNF-alpha;
KW   blood; chondrocyte cell; cell proliferation; cell differentiation; colon;
KW   adrenal; lung; breast; prostate; rectum; cervix; liver; genetic disorder;
KW   PCR primer.
XX
OS   Homo sapiens.
XX
PN   WO200168848-A2.
XX
PD   20-SEP-2001.
XX
PF   28-FEB-2001; 2001WO-US06520.
XX
PR   01-MAR-2000; 2000WO-US05601.
PR   02-MAR-2000; 2000WO-US05841.
PR   03-MAR-2000; 2000US-187202P.
PR   06-MAR-2000; 2000US-186968P.
PR   14-MAR-2000; 2000US-189320P.
PR   14-MAR-2000; 2000US-189328P.
PR   15-MAR-2000; 2000WO-US06884.
PR   21-MAR-2000; 2000US-190828P.
PR   21-MAR-2000; 2000US-191007P.
PR   21-MAR-2000; 2000US-191048P.
PR   21-MAR-2000; 2000US-191314P.
PR   28-MAR-2000; 2000US-192655P.
PR   29-MAR-2000; 2000US-193032P.
PR   29-MAR-2000; 2000US-193053P.
PR   30-MAR-2000; 2000WO-US08439.
PR   04-APR-2000; 2000US-194449P.
PR   04-APR-2000; 2000US-194647P.
PR   11-APR-2000; 2000US-195975P.
PR   11-APR-2000; 2000US-196000P.
PR   11-APR-2000; 2000US-196187P.
PR   11-APR-2000; 2000US-196690P.
PR   11-APR-2000; 2000US-196820P.
PR   18-APR-2000; 2000US-198121P.
PR   18-APR-2000; 2000US-198585P.
PR   25-APR-2000; 2000US-199397P.
PR   25-APR-2000; 2000US-199550P.
PR   25-APR-2000; 2000US-199654P.
PR   03-MAY-2000; 2000US-201516P.
PR   17-MAY-2000; 2000WO-US13705.
PR   22-MAY-2000; 2000WO-US14042.
PR   30-MAY-2000; 2000WO-US14941.
PR   02-JUN-2000; 2000WO-US15264.
PR   05-JUN-2000; 2000US-209832P.
PR   28-JUL-2000; 2000WO-US20710.
PR   22-AUG-2000; 2000US-0644848.
PR   24-AUG-2000; 2000WO-US23328.
PR   08-NOV-2000; 2000WO-US30952.
PR   01-DEC-2000; 2000WO-US32678.
PR   20-DEC-2000; 2000WO-US34956.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Chen J,  Desnoyers L,  Goddard A,  Godowski PJ,  Gurney AL;
PI   Pan J,  Smith V,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2001-602746/68.
DR   P-PSDB; AAU29236.
XX
PT   Novel nucleic acids encoding PRO polypeptides, used to diagnose the
PT   presence of tumours, such as prostate and breast tumours, in mammals and
PT   to screen for modulators of the compounds -
XX
PS   Claim 2; Fig 425; 774pp; English.
XX
CC   Sequences AAS45925-AAS46231 represent DNA molecules encoding and PCR
CC   primers for PRO polypeptides of the invention. The sequences of the
CC   invention can be used to detect the presence of a tumour in a mammal by
CC   comparing the level of expression of a PRO polypeptide in a test sample
CC   of cells from the animal and a control sample of normal cells, whereby a
CC   higher level of expression in the test sample indicates the presence of a
CC   tumour in the mammal. Mammals include dogs, cats, cattle, horses, sheep,
CC   pigs, goats and rabbits but are preferably human. The polypeptides can be
CC   used to stimulate tumour necrosis factor (TNF) alpha release from human
CC   blood, when contacted with it. A specific polypeptide can be used to
CC   stimulate the proliferation or differentiation of chondrocyte cells. The
CC   PRO proteins can be used to determine the presence of tumours and also
CC   susceptibility to tumour development, particularly adrenal, lung, colon,
CC   breast, prostate, rectal, cervical, or liver tumours, in mammalian
CC   subjects. The oligonucleotide probes specific for the PRO nucleic acids
CC   can be used for genetic analysis of individuals with genetic disorders.
XX
SQ   Sequence 1227 BP; 331 A; 325 C; 293 G; 278 T; 0 other;
```

```
  Query Match            99.3%;  Score 1064.2;  DB 22;  Length 1227;
  Best Local Similarity  99.7%;  Pred. No. 2.1e-279;
  Matches 1066;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       4 GCCGCCACCTCCGGAACAAGCCATGGTGGCGGCGACGGTGGCAGCGGCGTGGCTGCTCCT 63
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      12 gccgccacctccggaacaagccatggtggcggcgacggtggcagcggcgtggctgctcct 71

Qy      64 GTGGGCTGCGGCCTGCGCGCAGCAGGAGCAGGACTTCTACGACTTCAAGGCGGTCAACAT 123
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      72 gtgggctgcggcctgcgcgcagcaggagcaggacttctacgacttcaaggcggtcaacat 131

Qy     124 CCGGGGCAAACTGGTGTCGCTGGAGAAGTACCGCGGATCGGTGTCCCTGGTGGTGAATGT 183
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     132 ccggggcaaactggtgtcgctggagaagtaccgcggatcggtgtccctggtggtgaatgt 191

Qy     184 GGCCAGCGAGTGCGGCTTCACAGACCAGCACTACCGAGCCCTGCAGCAGCTGCAGCGAGA 243
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     192 ggccagcgagtgcggcttcacagaccagcactaccgagccctgcagcagctgcagcgaga 251

Qy     244 CCTGGGCCCCCACCACTTCAACGTGCTCGCCTTCCCCTGCAACCAGTTTGGCCAACAGGA 303
           |||||||||||||||| ||||||||||||||||||||||||||||||||||||||||||
Db     252 cctgggccccaccactttaacgtgctcgccttccctgcaaccagtttggccaacagga 311

Qy     304 GCCTGACAGCAACAAGGAGATTGAGAGCTTTGCCTGCCGCACCTACAGTGTCTCATTCCC 363
           |||||||||||||||||||||||||||||| ||||||||||||||||||||||||||||
Db     312 gcctgacagcaacaaggagattgagagctttgcccgccgcacctacagtgtctcattccc 371

Qy     364 CATGTTTAGCAAGATTGCAGTCACCGGTACTGGTGCCCATCCTGCCTTCAAGTACCTGGC 423
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     372 catgtttagcaagattgcagtcaccggtactggtgcccatcctgccttcaagtacctggc 431

Qy     424 CCAGACTTCTGGGAAGGAGCCCACCTGGAACTTCTGGAAGTACCTAGTAGCCCCAGATGG 483
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     432 ccagacttctgggaaggagcccacctggaacttctggaagtacctagtagccccagatgg 491

Qy     484 AAAGGTGGTAGGGGCTTGGGACCCAACTGTGTCAGTGGAGGAGGTCAGACTCCAGATCAC 543
           |||||||||||||||||||||||||||||||||||||||||||||| |||||||||||||
Db     492 aaaggtggtaggggcttgggacccaactgtgtcagtggaggaggtcagaccccagatcac 551

Qy     544 AGCGCTCGTGAGGAAGCTCATCCTACTGAAGCGAGAAGACTTATAACCACCGCGTCTCCT 603
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     552 agcgctcgtgaggaagctcatcctactgaagcgagaagacttataaccaccgcgtctcct 611

Qy     604 CCTCCACCACCTCATCCCGCCCACCTGTGTGGGGCTGACCAATGCAAACTCAAATGGTGC 663
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     612 cctccaccacctcatcccgcccacctgtgtggggctgaccaatgcaaactcaaatggtgc 671

Qy     664 TTCAAAGGGAGAGACCCACTGACTCTCCTTCCTTTACTCTTATGCCATTGGTCCCATCAT 723
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     672 ttcaaagggagagacccactgactctccttccttttactcttatgccattggtcccatcat 731

Qy     724 TCTTGTGGGGGAAAAATTCTAGTATTTTGATTATTTGAATCTTACAGCAACAAATAGGAA 783
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     732 tcttgtgggggaaaaattctagtattttgattatttgaatcttacagcaacaaataggaa 791

Qy     784 CTCCTGGCCAATGAGAGCTCTTGACCAGTGAATCACCAGCCGATACGAACGTCTTGCCAA 843
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     792 ctcctggccaatgagagctcttgaccagtgaatcaccagccgatacgaacgtcttgccaa 851

Qy     844 CAAAAATGTGTGGCAAATAGAAGTATATCAAGCAATAATCTCCCACCCAAGGCTTCTGTA 903
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     852 caaaaatgtgtggcaaatagaagtatatcaagcaataatctcccacccaaggcttctgta 911

Qy     904 AACTGGGACCAATGATTACCTCATAGGGCTGTTGTGAGGATTAGGATGAAATACCTGTGA 963
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     912 aactgggaccaatgattacctcatagggctgttgtgaggattaggatgaaatacctgtga 971

Qy     964 AAGTGCCTAGGCAGTGCCAGCCAAATAGGAGGCATTCAATGAACATTTTTTGCATATAAA 1023
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     972 aagtgcctaggcagtgccagccaaataggaggcattcaatgaacatttttgcatataaa 1031

Qy    1024 CCAAAAAATAACTTGTTATCAATAAAAACTTGCATCCAACATGAATTTC 1072
           ||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1032 ccaaaaaataacttgttatcaataaaaacttgcatccaacatgaatttc 1080


RESULT   9
AAF44159
ID   AAF44159 standard; cDNA; 1227 BP.
XX
AC   AAF44159;
XX
DT   02-APR-2001  (first entry)
XX
DE   Human PRO828 (UNQ469) nucleotide sequence SEQ ID NO:188.
XX
KW   Human; secreted and transmembrane protein; PRO; cytostatic;
KW   cell death; cancer; chromosomal mapping; gene mapping; tissue typing;
KW   diagnostic assay; ss.
XX
OS   Homo sapiens.
XX
PN   WO200073454-A1.
XX
PD   07-DEC-2000.
XX
PF   30-MAR-2000; 2000WO-US08439.
XX
PR   02-JUN-1999;   99WO-US12252.
PR   23-JUN-1999;   99US-0141037.
PR   07-JUL-1999;   99US-0143048.
PR   20-JUL-1999;   99US-0144758.
PR   26-JUL-1999;   99US-0145698.
PR   28-JUL-1999;   99US-0146222.
PR   17-AUG-1999;   99US-0149396.
PR   15-SEP-1999;   99WO-US21090.
PR   15-SEP-1999;   99WO-US21547.
PR   08-OCT-1999;   99US-0158663.
PR   30-NOV-1999;   99WO-US28313.
PR   01-DEC-1999;   99WO-US28301.
PR   16-DEC-1999;   99WO-US30095.
PR   20-DEC-1999;   99WO-US30911.
PR   05-JAN-2000; 2000WO-US00219.
PR   06-JAN-2000; 2000WO-US00376.
PR   11-FEB-2000; 2000WO-US03565.
PR   18-FEB-2000; 2000WO-US04341.
PR   22-FEB-2000; 2000WO-US04414.
PR   24-FEB-2000; 2000WO-US04914.
PR   24-FEB-2000; 2000WO-US05004.
PR   02-MAR-2000; 2000WO-US05841.
PR   15-MAR-2000; 2000WO-US06884.
PR   20-MAR-2000; 2000WO-US07377.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Ashkenazi AJ,  Baker KP,  Botstein D,  Desnoyers L,  Eaton DL;
PI   Ferrara N,  Fong S,  Gerber H,  Gerritsen ME,  Goddard A,  Godowski PJ;
PI   Grimaldi CJ,  Gurney AL,  Kljavin IJ,  Napier MA,  Pan J,  Paoni NF;
PI   Roy MA,  Stewart TA,  Tumas D,  Watanabe CK,  Williams PM,  Wood WI;
PI   Zhang Z;
XX
DR   WPI; 2001-032160/04.
DR   P-PSDB; AAB65200.
XX
PT   PRO polynucleotides used to produce polypeptides used to target
PT   bioactive molecules such as toxins, radiolabels or antibodies, to
PT   specific cells, to cause targeted cell death -
XX
PS   Claim 2; Fig 119; 935pp; English.
XX
CC   The present invention describes human secreted and transmembrane PRO
CC   proteins. The PRO proteins have cytostatic activity. The PRO proteins
CC   can be used for targeted delivery of bioactive molecules, such as
CC   toxins, radiolabels or antibodies, that cause cell death. PRO nucleotide
CC   sequences, and their fragments, can be used as hybridisation probes, in
```

```
CC   chromosomal and gene mapping, and in the generation of anti-sense RNA
CC   and DNA. They may also be used to produce transgenic animals which are
CC   used to develop and screen therapeutically useful reagents. The PRO
CC   nucleotide and protein sequence can be used for tissue typing and in
CC   treating cancer. Anti-PRO antibodies can be used in diagnostic assays.
CC   AAF44270 to AAF44470 represent PCR primers and hybridisation probes used
CC   in the isolation of human PRO sequences. AAF44087 to AAF44269 and
CC   AAB65154 to AAB65300 represent human PRO polynucleotide and protein
CC   sequences given in the exemplification of the present invention.
XX
SQ   Sequence 1227 BP; 331 A; 325 C; 293 G; 278 T; 0 other;


  Query Match             99.3%;  Score 1064.2;  DB 22;  Length 1227;
  Best Local Similarity   99.7%;  Pred. No. 2.1e-279;
  Matches 1066;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy      4 GCCGCCACCTCCGGAACAAGCCATGGTGGCGGCGACGGTGGCAGCGGCGTGGCTGCTCCT 63
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     12 gccgccacctccggaacaagccatggtggcggcgacggtggcagcggcgtggctgctcct 71

Qy     64 GTGGGCTGCGGCCTGCGCGCAGCAGGAGCAGGACTTCTACGACTTCAAGGCGGTCAACAT 123
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     72 gtgggctgcggcctgcgcgcagcaggagcaggacttctacgacttcaaggcggtcaacat 131

Qy    124 CCGGGGCAAACTGGTGTCGCTGGAGAAGTACCGCGGATCGGTGTCCCTGGTGGTGAATGT 183
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    132 ccggggcaaactggtgtcgctggagaagtaccgcggatcggtgtccctggtggtgaatgt 191

Qy    184 GGCCAGCGAGTGCGGCTTCACAGACCAGCACTACCGAGCCCTGCAGCAGCTGCAGCGAGA 243
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    192 ggccagcgagtgcggcttcacagaccagcactaccgagccctgcagcagctgcagcgaga 251

Qy    244 CCTGGGCCCCCCACCACTTCAACGTGCTCGCCTTCCCCTGCAACCAGTTTGGCCAACAGGA 303
          |||||||||||||||||| ||||||||||||||||||||||||||||||||||||||||
Db    252 cctgggcccccaccactttaacgtgctcgccttccccctgcaaccagtttggccaacagga 311

Qy    304 GCCTGACAGCAACAAGGAGATTGAGAGCTTTGCCTGCCGCACCTACAGTGTCTCATTCCC 363
          |||||||||||||||||||||||||||||| ||||||||||||||||||||||||||||
Db    312 gcctgacagcaacaaggagattgagagctttgcccgccgcacctacagtgtctcattccc 371

Qy    364 CATGTTTAGCAAGATTGCAGTCACCGGTACTGGTGCCCATCCTGCCTTCAAGTACCTGGC 423
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    372 catgtttagcaagattgcagtcaccggtactggtgcccatcctgccttcaagtacctggc 431

Qy    424 CCAGACTTCTGGGAAGGAGCCCACCTGGAACTTCTGGAAGTACCTAGTAGCCCCAGATGG 483
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    432 ccagacttctgggaaggagcccacctggaacttctggaagtacctagtagccccagatgg 491

Qy    484 AAAGGTGGTAGGGGCTTGGGACCCAACTGTGTCAGTGGAGGAGGTCAGACTCCAGATCAC 543
          |||||||||||||||||||||||||||||||||||||||||||||| ||||||||||||
Db    492 aaaggtggtaggggcttgggacccaactgtgtcagtggaggaggtcagaccccagatcac 551

Qy    544 AGCGCTCGTGAGGAAGCTCATCCTACTGAAGCGAGAAGACTTATAACCACCGCGTCTCCT 603
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    552 agcgctcgtgaggaagctcatcctactgaagcgagaagacttataaccaccgcgtctcct 611

Qy    604 CCTCCACCACCTCATCCCGCCCACCTGTGTGGGGCTGACCAATGCAAACTCAAATGGTGC 663
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    612 cctccaccacctcatcccgcccacctgtgtggggctgaccaatgcaaactcaaatggtgc 671

Qy    664 TTCAAAGGGAGAGACCCACTGACTCTCCTTCCTTTACTCTTATGCCATTGGTCCCATCAT 723
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    672 ttcaaagggagagacccactgactctccttcctttactcttatgccattggtcccatcat 731

Qy    724 TCTTGTGGGGGAAAAATTCTAGTATTTTGATTATTTGAATCTTACAGCAACAAATAGGAA 783
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    732 tcttgtgggggaaaaattctagtattttgattatttgaatcttacagcaacaaataggaa 791

Qy    784 CTCCTGGCCAATGAGAGCTCTTGACCAGTGAATCACCAGCCGATACGAACGTCTTGCCAA 843
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    792 ctcctggccaatgagagctcttgaccagtgaatcaccagccgatacgaacgtcttgccaa 851

Qy    844 CAAAAATGTGTGGCAAATAGAAGTATATCAAGCAATAATCTCCCACCCAAGGCTTCTGTA 903
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    852 caaaaatgtgtggcaaatagaagtatatcaagcaataatctcccacccaaggcttctgta 911

Qy    904 AACTGGGACCAATGATTACCTCATAGGGCTGTTGTGAGGATTAGGATGAAATACCTGTGA 963
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    912 aactgggaccaatgattacctcatagggctgttgtgaggattaggatgaaatacctgtga 971

Qy    964 AAGTGCCTAGGCAGTGCCAGCCAAATAGGAGGCATTCAATGAACATTTTTTGCATATAAA 1023
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    972 aagtgcctaggcagtgccagccaaataggaggcattcaatgaacatttttgcatataaa 1031

Qy   1024 CCAAAAAATAACTTGTTATCAATAAAAACTTGCATCCAACATGAATTTC 1072
          |||||||||||||||||||||||||||||||||||||||||||||||||
Db   1032 ccaaaaaataacttgttatcaataaaaacttgcatccaacatgaatttc 1080


RESULT  10
AAI58027
ID   AAI58027 standard; cDNA; 1100 BP.
XX
AC   AAI58027;
XX
DT   22-OCT-2001  (first entry)
XX
DE   Human polynucleotide SEQ ID NO 230.
XX
KW   Human; nootropic; immunosuppressant; cytostatic; gene therapy; cancer;
KW   peripheral nervous system; neuropathy; central nervous system; CNS;
KW   Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
KW   amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;
KW   chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
KW   leukaemia; ss.
XX
OS   Homo sapiens.
XX
PN   WO200153312-A1.
XX
PD   26-JUL-2001.
XX
PF   26-DEC-2000; 2000WO-US34263.
XX
PR   21-JAN-2000; 2000US-0488725.
PR   25-APR-2000; 2000US-0552317.
PR   09-JUL-2000; 2000US-0598042.
PR   19-JUL-2000; 2000US-0620312.
PR   03-AUG-2000; 2000US-0653450.
PR   14-SEP-2000; 2000US-0662191.
PR   19-OCT-2000; 2000US-0693036.
PR   29-NOV-2000; 2000US-0727344.
XX
PA   (HYSE-) HYSEQ INC.
XX
PI   Tang YT,  Liu C,  Asundi V,  Chen R,  Ma Y,  Qian XB,  Ren F,  Wang D;
PI   Wang J,  Wang Z,  Wehrman T,  Xu C,  Xue AJ,  Yang Y,  Zhang J;
PI   Zhao QA,  Zhou P,  Goodrich R,  Drmanac RT;
XX
DR   WPI; 2001-442253/47.
DR   P-PSDB; AAM38871.
XX
PT   Novel nucleic acids and polypeptides, useful for treating disorders
PT   such as central nervous system injuries -
XX
PS   Claim 1; SEQ ID NO 230; 10078pp; English.
XX
CC   The invention relates to human nucleic acids (AAI57798-AAI61369) and
CC   the encoded polypeptides (AAM38642-AAM42213) with nootropic,
CC   immunosuppressant and cytostatic activity. The polynucleotides are useful
CC   in gene therapy. A composition containing a polypeptide or polynucleotide
CC   of the invention may be used to treat diseases of the peripheral nervous
CC   system, such as peripheral nervous injuries, peripheral neuropathy and
CC   localised neuropathies and central nervous system diseases, such as
CC   Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
```

```
CC   lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
CC   utilisation of the activities such as: Immune system suppression,
CC   Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
CC   and thrombolytic activity, cancer diagnosis and therapy, drug screening,
CC   assays for receptor activity, arthritis and inflammation, leukaemias and
CC   C.N.S disorders.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification.
XX
SQ   Sequence 1100 BP; 288 A; 305 C; 277 G; 230 T; 0 other;


  Query Match             99.2%;  Score 1063.2;  DB 22;  Length 1100;
  Best Local Similarity   99.7%;  Pred. No. 3.7e-279;
  Matches 1065;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1 GACGCCGCCACCTCCGGAACAAGCCATGGTGGCGGCGACGGTGGCAGCGGCGTGGCTGCT 60
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      23 gacgccgccacctccggaacaagccatggtggcggcgacggtggcagcggcgtggctgct 82

Qy      61 CCTGTGGGCTGCGGCCTGCGCGCAGCAGGAGCAGGACTTCTACGACTTCAAGGCGGTCAA 120
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      83 cctgtgggctgcggcctgcgcgcagcaggagcaggacttctacgacttcaaggcggtcaa 142

Qy     121 CATCCGGGGCAAACTGGTGTCGCTGGAGAAGTACCGCGGATCGGTGTCCCTGGTGGTGAA 180
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     143 catccggggcaaactggtgtcgctggagaagtaccgcggatcggtgtccctggtggtgaa 202

Qy     181 TGTGGCCAGCGAGTGCGGCTTCACAGACCAGCACTACCGAGCCCTGCAGCAGCTGCAGCG 240
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     203 tgtggccagcgagtgcggcttcacagaccagcactaccgagccctgcagcagctgcagcg 262

Qy     241 AGACCTGGGCCCCCACCACTTCAACGTGCTCGCCTTCCCCTGCAACCAGTTTGGCCAACA 300
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     263 agacctgggccccaccacttcaacgtgctcgccttcccctgcaaccagtttggccaaca 322

Qy     301 GGAGCCTGACAGCAACAAGGAGATTGAGAGCTTTGCCTGCCGCACCTACAGTGTCTCATT 360
          |||||||||||||||||||||||||||||||| ||||||||||||||||||||||||||
Db     323 ggagcctgacagcaacaaggagattgagagctttgcccgccgcacctacagtgtctcatt 382

Qy     361 CCCCATGTTTAGCAAGATTGCAGTCACCGGTACTGGTGCCCATCCTGCCTTCAAGTACCT 420
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     383 ccccatgtttagcaagattgcagtcaccggtactggtgcccatcctgccttcaagtacct 442

Qy     421 GGCCCAGACTTCTGGGAAGGAGCCCACCTGGAACTTCTGGAAGTACCTAGTAGCCCCAGA 480
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     443 ggcccagacttctgggaaggagcccacctggaacttctggaagtacctagtagccccaga 502

Qy     481 TGGAAAGGTGGTAGGGGCTTGGGACCCAACTGTGTCAGTGGAGGAGGTCAGACTCCAGAT 540
          |||||||||||||||||||||||||||||||||||||||||||||||| ||||||
Db     503 tggaaaggtggtaggggcttgggacccaactgtgtcagtggaggaggtcagaccccagat 562

Qy     541 CACAGCGCTCGTGAGGAAGCTCATCCTACTGAAGCGAGAAGACTTATAACCACCGCGTCT 600
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     563 cacagcgctcgtgaggaagctcatcctactgaagcgagaagacttataaccaccgcgtct 622

Qy     601 CCTCCTCCACCACCTCATCCCGCCCACCTGTGTGGGGCTGACCAATGCAAACTCAAATGG 660
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     623 cctcctccaccacctcatcccgcccacctgtgtggggctgaccaatgcaaactcaaatgg 682

Qy     661 TGCTTCAAAGGGAGAGACCCACTGACTCTCCTTCCTTTACTCTTATGCCATTGGTCCCAT 720
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     683 tgcttcaaagggagagacccactgactctccttcctttactcttatgccattggtcccat 742

Qy     721 CATTCTTGTGGGGGAAAAATTCTAGTATTTTGATTATTTGAATCTTACAGCAACAAATAG 780
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     743 cattcttgtgggggaaaaattctagtattttgattatttgaatcttacagcaacaaatag 802

Qy     781 GAACTCCTGGCCAATGAGAGCTCTTGACCAGTGAATCACCAGCCGATACGAACGTCTTGC 840
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     803 gaactcctggccaatgagagctcttgaccagtgaatcaccagccgatacgaacgtcttgc 862

Qy     841 CAACAAAAATGTGTGGCAAATAGAAGTATATCAAGCAATAATCTCCCACCCAAGGCTTCT 900
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     863 caacaaaaatgtgtggcaaatagaagtatatcaagcaataatctcccacccaaggcttct 922

Qy     901 GTAAACTGGGACCAATGATTACCTCATAGGGCTGTTGTGAGGATTAGGATGAAATACCTG 960
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     923 gtaaactgggaccaatgattacctcatagggctgttgtgaggattaggatgaaatacctg 982

Qy     961 TGAAAGTGCCTAGGCAGTGCCAGCCAAATAGGAGGCATTCAATGAACATTTTTTGCATAT 1020
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     983 tgaaagtgcctaggcagtgccagccaaataggaggcattcaatgaacatttttgcatat 1042

Qy    1021 AAACCAAAAAATAACTTGTTATCAATAAAAACTTGCATCCAACATGAA 1068
           ||| ||||||||||||||||||||||||||||||||||||||||||||
Db    1043 aaaacaaaaaataacttgttatcaataaaaacttgcatccaacatgaa 1090


RESULT  11
AAH06810
ID   AAH06810 standard; cDNA; 872 BP.
XX
AC   AAH06810;
XX
DT   26-JUN-2001  (first entry)
XX
DE   Human cDNA clone (5'-primer) SEQ ID NO:3645.
XX
KW   Human; primer; detection; diagnosis; antisense therapy; gene therapy; ss.
XX
OS   Homo sapiens.
XX
PN   EP1074617-A2.
XX
PD   07-FEB-2001.
XX
PF   28-JUL-2000; 2000EP-0116126.
XX
PR   29-JUL-1999;   99JP-0248036.
PR   27-AUG-1999;   99JP-0300253.
PR   11-JAN-2000;  2000JP-0118776.
PR   02-MAY-2000;  2000JP-0183767.
PR   09-JUN-2000;  2000JP-0241899.
XX
PA   (HELI-) HELIX RES INST.
XX
PI   Ota T,  Isogai T,  Nishikawa T,  Hayashi K,  Saito K,  Yamamoto J;
PI   Ishii S,  Sugiyama T,  Wakamatsu A,  Nagai K,  Otsuki T;
XX
DR   WPI; 2001-318749/34.
XX
PT   Primer sets for synthesizing polynucleotides, particularly the 5602
PT   full-length cDNAs defined in the specification, and for the detection
PT   and/or diagnosis of the abnormality of the proteins encoded by the
PT   full-length cDNAs -
XX
PS   Claim 1; SEQ ID 3645; 2537pp + CD ROM; English.
XX
CC   The present invention describes primer sets for synthesising 5602
CC   full-length cDNAs defined in the specification. Where a primer set
CC   comprises: (a) an oligo-dT primer and an oligonucleotide complementary
CC   to the complementary strand of a polynucleotide which comprises one of
CC   the 5602 nucleotide sequences defined in the specification, where the
CC   oligonucleotide comprises at least 15 nucleotides; or (b) a combination
CC   of an oligonucleotide comprising a sequence complementary to the
CC   complementary strand of a polynucleotide which comprises a 5'-end
CC   sequence and an oligonucleotide comprising a sequence complementary to a
CC   polynucleotide which comprises a 3'-end sequence, where the
CC   oligonucleotide comprises at least 15 nucleotides and the combination of
CC   the 5'-end sequence/3'-end sequence is selected from those defined in
CC   the specification. The primer sets can be used in antisense therapy and
CC   in gene therapy. The primers are useful for synthesising polynucleotides,
CC   particularly full-length cDNAs. The primers are also useful for the
CC   detection and/or diagnosis of the abnormality of the proteins encoded by
CC   the full-length cDNAs. The primers allow obtaining of the full-length
```

```
CC   cDNAs easily without any specialised methods. AAH03166 to AAH13628 and
CC   AAH13633 to AAH18742 represent human cDNA sequences; AAB92446 to
CC   AAB95893 represent human amino acid sequences; and AAH13629 to AAH13632
CC   represent oligonucleotides, all of which are used in the exemplification
CC   of the present invention.
XX
SQ   Sequence 872 BP; 197 A; 259 C; 233 G; 183 T; 0 other;


  Query Match            79.0%;  Score 846.8;  DB 22;  Length 872;
  Best Local Similarity  99.2%;  Pred. No. 2.6e-220;
  Matches  851;  Conservative    0;  Mismatches    7;  Indels    0;  Gaps    0;

Qy       1 GACGCCGCCACCTCCGGAACAAGCCATGGTGGCGGCGACGGTGGCAGCGGCGTGGCTGCT 60
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      15 gacgccgccacctccggaacaagccatggtggcggcgacggtggcagcggcgtggctgct 74

Qy      61 CCTGTGGGCTGCGGCCTGCGCGCAGCAGGAGCAGGACTTCTACGACTTCAAGGCGGTCAA 120
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      75 cctgtgggctgcggcctgcgcgcagcaggagcaggacttctacgacttcaaggcggtcaa 134

Qy     121 CATCCGGGGCAAACTGGTGTCGCTGGAGAAGTACCGCGGATCGGTGTCCCTGGTGGTGAA 180
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     135 catccggggcaaactggtgtcgctggagaagtaccgcggatcggtgtccctggtggtgaa 194

Qy     181 TGTGGCCAGCGAGTGCGGCTTCACAGACCAGCACTACCGAGCCCTGCAGCAGCTGCAGCG 240
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     195 tgtggccagcgagtgcggcttcacagaccagcactaccgagccctgcagcagctgcagcg 254

Qy     241 AGACCTGGGCCCCCACCACTTCAACGTGCTCGCCTTCCCCTGCAACCAGTTTGGCCAACA 300
          |||||||||||||||||||| ||||||||||||||||||||||||||||||||||||||
Db     255 agacctgggcccccaccacttaacgtgctcgccttccccctgcaaccagtttggccaaca 314

Qy     301 GGAGCCTGACAGCAACAAGGAGATTGAGAGCTTTGCCTGCCGCACCTACAGTGTCTCATT 360
          |||||||||||||||||||||||||||||||||||| ||||||||||||||||||||||
Db     315 ggagcctgacagcaacaaggagattgagagctttgcccgccgcacctacagtgtctcatt 374

Qy     361 CCCCATGTTTAGCAAGATTGCAGTCACCGGTACTGGTGCCCATCCTGCCTTCAAGTACCT 420
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     375 ccccatgtttagcaagattgcagtcaccggtactggtgcccatcctgccttcaagtacct 434

Qy     421 GGCCCAGACTTCTGGGAAGGAGCCCACCTGGAACTTCTGGAAGTACCTAGTAGCCCCAGA 480
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     435 ggcccagacttctgggaaggagcccacctggaacttctggaagtacctagtagccccaga 494

Qy     481 TGGAAAGGTGGTAGGGGCTTGGGACCCAACTGTGTCAGTGGAGGAGGTCAGACTCCAGAT 540
          |||||||||||||||||||||||||||||||||||||||||||||||||||| ||||||
Db     495 tggaaaggtggtaggggcttgggacccaactgtgtcagtggaggaggtcagaccccagat 554

Qy     541 CACAGCGCTCGTGAGGAAGCTCATCCTACTGAAGCGAGAAGACTTATAACCACCGCGTCT 600
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     555 cacagcgctcgtgaggaagctcatcctactgaagcgagaagacttataaccaccgcgtct 614

Qy     601 CCTCCTCCACCACCTCATCCCGCCCACCTGTGTGGGGCTGACCAATGCAAACTCAAATGG 660
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     615 cctcctccaccacctcatcccgcccacctgtgtggggctgaccaatgcaaactcaaatgg 674

Qy     661 TGCTTCAAAGGGAGAGACCCACTGACTCTCCTTCCTTTACTCTTATGCCATTGGTCCCAT 720
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     675 tgcttcaaagggagagacccactgactctccttcctttactcttatgccattggtcccat 734

Qy     721 CATTCTTGTGGGGGAAAAATTCTAGTATTTTGATTATTTGAATCTTACAGCAACAAATAG 780
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     735 cattcttgtgggggaaaaattctagtattttgattatttgaatcttacagcaacaaatag 794

Qy     781 GAACTCCTGGCCAATGAGAGCTCTTGACCAGTGAATCACCAGCCGATACGAACGTCTTGC 840
          ||||| |||| ||||||||  ||||||||||||||||||||||||||||||||||||||
Db     795 gaacttctgggcaatgagacttcttgaccagtgaatcaccagccgatacgaacgtcttgc 854

Qy     841 CAACAAAAATGTGTGGCA 858
          ||||||||||||||||||
Db     855 caacaaaaatgtgtggca 872
```

```
RESULT  12
AAH71016/c
ID   AAH71016 standard; cDNA; 751 BP.
XX
AC   AAH71016;
XX
DT   19-SEP-2001  (first entry)
XX
DE   Human cervical cancer marker nucleic acid 2290.
XX
KW   Cervical cancer; cytostatic; pre-malignant condition; gene therapy; ss.
XX
OS   Homo sapiens.
XX
PN   WO200142467-A2.
XX
PD   14-JUN-2001.
XX
PF   08-DEC-2000; 2000WO-US33312.
XX
PR   08-DEC-1999;   99US-0169681.
PR   21-DEC-1999;   99US-0171350.
PR   14-MAR-2000; 2000US-0189315.
PR   12-MAY-2000; 2000US-0203791.
PR   09-JUN-2000; 2000US-0210600.
PR   21-JUL-2000; 2000US-0220114.
XX
PA   (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.
XX
PI   Schlegel R,  Deeds J,  Berger A,  Zhao X;
XX
DR   WPI; 2001-375006/39.
XX
PT   New isolated nucleic acid for diagnosing and treating cervical cancer
PT   and for assessing and detecting compounds for treating the cancer -
XX
PS   Claim 1; Page 484; 1051pp; English.
XX
CC   The invention relates to novel genes (AAH68727-AAH73383) associated with
CC   cervical cancer with cytostatic activity. The nucleic acids and encoded
CC   polypeptides are useful: to assess if a patient is afflicted with
CC   cervical cancer or has a pre-malignant condition; to monitor the
CC   progression of cervical cancer or a premalignant condition in a patient;
CC   and to select and/or assess the efficacy of a compound or therapy for
CC   inhibiting cervical cancer in a patient. The nucleic acids may also be
CC   useful for gene therapy.
XX
SQ   Sequence 751 BP; 194 A; 141 C; 143 G; 269 T; 4 other;


  Query Match            37.9%;  Score 406.2;  DB 22;  Length 751;
  Best Local Similarity  99.1%;  Pred. No. 2e-100;
  Matches  419;  Conservative    0;  Mismatches    3;  Indels    1;  Gaps    1;

Qy     650 AACTCAAATGGTGCTTCAAAGGGAGAGACCCACTGACTCTCCTTCCTTTACTCTTATGCC 709
           |||||||  ||||||||  ||||||||||||||||||||||||||||||||||||||||
Db     745 AACTCAATGGGTGCTTC-AAGGGAGAGACCCACTGACTCTCCTTCCTTTACTCTTATGCC 687

Qy     710 ATTGGTCCCATCATTCTTGTGGGGGAAAAATTCTAGTATTTTGATTATTTGAATCTTACA 769
           | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     686 ACTGGTCCCATCATTCTTGTGGGGGAAAAATTCTAGTATTTTGATTATTTGAATCTTACA 627

Qy     770 GCAACAAATAGGAACTCCTGGCCAATGAGAGCTCTTGACCAGTGAATCACCAGCCGATAC 829
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     626 GCAACAAATAGGAACTCCTGGCCAATGAGAGCTCTTGACCAGTGAATCACCAGCCGATAC 567

Qy     830 GAACGTCTTGCCAACAAAAATGTGTGGCAAATAGAAGTATATCAAGCAATAATCTCCCAC 889
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     566 GAACGTCTTGCCAACAAAAATGTGTGGCAAATAGAAGTATATCAAGCAATAATCTCCCAC 507

Qy     890 CCAAGGCTTCTGTAAACTGGGACCAATGATTACCTCATAGGGCTGTTGTGAGGATTAGGA 949
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
```

```
Db     506 CCAAGGCTTCTGTAAACTGGGACCAATGATTACCTCATAGGGCTGTTGTGAGGATTAGGA 447

Qy     950 TGAAATACCTGTGAAAGTGCCTAGGCAGTGCCAGCCAAATAGGAGGCATTCAATGAACAT 1009
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     446 TGAAATACCTGTGAAAGTGCCTAGGCAGTGCCAGCCAAATAGGAGGCATTCAATGAACAT 387

Qy    1010 TTTTTGCATATAAACCAAAAAATAACTTGTTATCAATAAAAACTTGCATCCAACATGAAT 1069
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     386 TTTTTGCATATAAACCAAAAAATAACTTGTTATCAATAAAAACTTGCATCCAACATGAAT 327

Qy    1070 TTC 1072
           |||
Db     326 TTC 324


RESULT  13
AAH11842/c
ID   AAH11842 standard; cDNA; 528 BP.
XX
AC   AAH11842;
XX
DT   26-JUN-2001  (first entry)
XX
DE   Human cDNA clone (3'-primer) SEQ ID NO:8677.
XX
KW   Human; primer; detection; diagnosis; antisense therapy; gene therapy; ss.
XX
OS   Homo sapiens.
XX
PN   EP1074617-A2.
XX
PD   07-FEB-2001.
XX
PF   28-JUL-2000; 2000EP-0116126.
XX
PR   29-JUL-1999;   99JP-0248036.
PR   27-AUG-1999;   99JP-0300253.
PR   11-JAN-2000; 2000JP-0118776.
PR   02-MAY-2000; 2000JP-0183767.
PR   09-JUN-2000; 2000JP-0241899.
XX
PA   (HELI-) HELIX RES INST.
XX
PI   Ota T,  Isogai T,  Nishikawa T,  Hayashi K,  Saito K,  Yamamoto J;
PI   Ishii S,  Sugiyama T,  Wakamatsu A,  Nagai K,  Otsuki T;
XX
DR   WPI; 2001-318749/34.
XX
PT   Primer sets for synthesizing polynucleotides, particularly the 5602
PT   full-length cDNAs defined in the specification, and for the detection
PT   and/or diagnosis of the abnormality of the proteins encoded by the
PT   full-length cDNAs -
XX
PS   Claim 3; SEQ ID 8677; 2537pp + CD ROM; English.
XX
CC   The present invention describes primer sets for synthesising 5602
CC   full-length cDNAs defined in the specification. Where a primer set
CC   comprises: (a) an oligo-dT primer and an oligonucleotide complementary
CC   to the complementary strand of a polynucleotide which comprises one of
CC   the 5602 nucleotide sequences defined in the specification, where the
CC   oligonucleotide comprises at least 15 nucleotides; or (b) a combination
CC   of an oligonucleotide comprising a sequence complementary to the
CC   complementary strand of a polynucleotide which comprises a 5'-end
CC   sequence and an oligonucleotide comprising a sequence complementary to a
CC   polynucleotide which comprises a 3'-end sequence, where the
CC   oligonucleotide comprises at least 15 nucleotides and the combination of
CC   the 5'-end sequence/3'-end sequence is selected from those defined in
CC   the specification. The primer sets can be used in antisense therapy and
CC   in gene therapy. The primers are useful for synthesising polynucleotides,
CC   particularly full-length cDNAs. The primers are also useful for the
CC   detection and/or diagnosis of the abnormality of the proteins encoded by
CC   the full-length cDNAs. The primers allow obtaining of the full-length
CC   cDNAs easily without any specialised methods. AAH03166 to AAH13628 and
CC   AAH13633 to AAH18742 represent human cDNA sequences; AAB92446 to
CC   AAB95893 represent human amino acid sequences; and AAH13629 to AAH13632
CC   represent oligonucleotides, all of which are used in the exemplification
CC   of the present invention.
XX
SQ   Sequence 528 BP; 153 A; 89 C; 108 G; 177 T; 1 other;


  Query Match             33.6%;  Score 360.2;  DB 22;  Length 528;
  Best Local Similarity   98.9%;  Pred. No. 5.5e-88;
  Matches  373;  Conservative    0;  Mismatches    3;  Indels    1;  Gaps    1;

Qy     696 TTTACTCTTATGCCATTGGTCCCATCATTCTTGTGGGGGAAAAATTCTAGTATTTTGATT 755
           ||   |||||||||||||||||||||||||| ||||||||||||||||||||||||||||
Db     518 TTACTTCTTATGCCATTGGTCCCATCATTCTTG-GGGGGAAAAATTCTAGTATTTTGATT 460

Qy     756 ATTTGAATCTTACAGCAACAAATAGGAACTCCTGGCCAATGAGAGCTCTTGACCAGTGAA 815
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     459 ATTTGAATCTTACAGCAACAAATAGGAACTCCTGGCCAATGAGAGCTCTTGACCAGTGAA 400

Qy     816 TCACCAGCCGATACGAACGTCTTGCCAACAAAAATGTGTGGCAAATAGAAGTATATCAAG 875
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     399 TCACCAGCCGATACGAACGTCTTGCCAACAAAAATGTGTGGCAAATAGAAGTATATCAAG 340

Qy     876 CAATAATCTCCCACCCAAGGCTTCTGTAAACTGGGACCAATGATTACCTCATAGGGCTGT 935
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     339 CAATAATCTCCCACCCAAGGCTTCTGTAAACTGGGACCAATGATTACCTCATAGGGCTGT 280

Qy     936 TGTGAGGATTAGGATGAAATACCTGTGAAAGTGCCTAGGCAGTGCCAGCCAAATAGGAGG 995
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     279 TGTGAGGATTAGGATGAAATACCTGTGAAAGTGCCTAGGCAGTGCCAGCCAAATAGGAGG 220

Qy     996 CATTCAATGAACATTTTTTGCATATAAACCAAAAAATAACTTGTTATCAATAAAAACTTG 1055
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     219 CATTCAATGAACATTTTTTGCATATAAACCAAAAAATAACTTGTTATCAATAAAAACTTG 160

Qy    1056 CATCCAACATGAATTTC 1072
           |||||||||||||||||
Db     159 CATCCAACATGAATTTC 143


RESULT  14
AAH72087/c
ID   AAH72087 standard; cDNA; 468 BP.
XX
AC   AAH72087;
XX
DT   19-SEP-2001  (first entry)
XX
DE   Human cervical cancer marker nucleic acid 3361.
XX
KW   Cervical cancer; cytostatic; pre-malignant condition; gene therapy; ss.
XX
OS   Homo sapiens.
XX
PN   WO200142467-A2.
XX
PD   14-JUN-2001.
XX
PF   08-DEC-2000; 2000WO-US33312.
XX
PR   08-DEC-1999;   99US-0169681.
PR   21-DEC-1999;   99US-0171350.
PR   14-MAR-2000; 2000US-0189315.
PR   12-MAY-2000; 2000US-0203791.
PR   09-JUN-2000; 2000US-0210600.
PR   21-JUL-2000; 2000US-0220114.
XX
PA   (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.
XX
PI   Schlegel R,  Deeds J,  Berger A,  Zhao X;
XX
DR   WPI; 2001-375006/39.
```

```
XX
PT   New isolated nucleic acid for diagnosing and treating cervical cancer
PT   and for assessing and detecting compounds for treating the cancer -
XX
PS   Claim 1; Page 652; 1051pp; English.
XX
CC   The invention relates to novel genes (AAH68727-AAH73383) associated with
CC   cervical cancer with cytostatic activity. The nucleic acids and encoded
CC   polypeptides are useful: to assess if a patient is afflicted with
CC   cervical cancer or has a pre-malignant condition; to monitor the
CC   progression of cervical cancer or a premalignant condition in a patient;
CC   and to select and/or assess the efficacy of a compound or therapy for
CC   inhibiting cervical cancer in a patient. The nucleic acids may also be
CC   useful for gene therapy.
XX
SQ   Sequence 468 BP; 131 A; 84 C; 94 G; 159 T; 0 other;


  Query Match             33.2%;  Score 356;  DB 22;  Length 468;
  Best Local Similarity   100.0%;  Pred. No. 7.3e-87;
  Matches  356;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy     717 CCATCATTCTTGTGGGGGAAAAATTCTAGTATTTTGATTATTTGAATCTTACAGCAACAA 776
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     468 CCATCATTCTTGTGGGGGAAAAATTCTAGTATTTTGATTATTTGAATCTTACAGCAACAA 409

Qy     777 ATAGGAACTCCTGGCCAATGAGAGCTCTTGACCAGTGAATCACCAGCCGATACGAACGTC 836
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     408 ATAGGAACTCCTGGCCAATGAGAGCTCTTGACCAGTGAATCACCAGCCGATACGAACGTC 349

Qy     837 TTGCCAACAAAAATGTGTGGCAAATAGAAGTATATCAAGCAATAATCTCCCACCCAAGGC 896
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     348 TTGCCAACAAAAATGTGTGGCAAATAGAAGTATATCAAGCAATAATCTCCCACCCAAGGC 289

Qy     897 TTCTGTAAACTGGGACCAATGATTACCTCATAGGGCTGTTGTGAGGATTAGGATGAAATA 956
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     288 TTCTGTAAACTGGGACCAATGATTACCTCATAGGGCTGTTGTGAGGATTAGGATGAAATA 229

Qy     957 CCTGTGAAAGTGCCTAGGCAGTGCCAGCCAAATAGGAGGCATTCAATGAACATTTTTTGC 1016
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     228 CCTGTGAAAGTGCCTAGGCAGTGCCAGCCAAATAGGAGGCATTCAATGAACATTTTTTGC 169

Qy    1017 ATATAAACCAAAAAATAACTTGTTATCAATAAAAACTTGCATCCAACATGAATTTC 1072
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     168 ATATAAACCAAAAAATAACTTGTTATCAATAAAAACTTGCATCCAACATGAATTTC 113


RESULT  15
AAA96342
ID   AAA96342 standard; cDNA; 1342 BP.
XX
AC   AAA96342;
XX
DT   08-FEB-2001  (first entry)
XX
DE   cDNA encoding a novel polypeptide designated PRO1785.
XX
KW   Secreted protein; transmembrane protein; PRO1484; PRO4334; PRO1122;
KW   PRO1889; PRO1890; PRO1887; PRO1785; PRO4353; PRO4357; PRO4405; PRO4356;
KW   PRO4352; PRO4380; PRO4354; PRO4408; PRO5737; PRO4425; PRO5990; PRO6030;
KW   PRO4424; PRO4422; PRO4430; PRO4499; tumour; obesity; diabetes;
KW   insulinemia; kidney disorder; Bergers disease; nephropathy;
KW   Schonlein-Henoch purpura; celiac disease; dermatitis herpetiformis;
KW   Crohns disease; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   CDS             2..631
FT                   /*tag=  a
FT                   /transl_except= (pos: 355..357, aa: Asp)
FT   sig_peptide     2..94
FT                   /*tag=  b
XX
PN   WO200056889-A2.
XX
PD   28-SEP-2000.
XX
PF   01-MAR-2000; 2000WO-US05601.
XX
PR   23-MAR-1999;   99US-0125774.
PR   23-MAR-1999;   99US-0125778.
PR   24-MAR-1999;   99US-0125826.
PR   31-MAR-1999;   99US-0127035.
PR   05-APR-1999;   99US-0127706.
PR   21-APR-1999;   99US-0130359.
PR   27-APR-1999;   99US-0131270.
PR   27-APR-1999;   99US-0131272.
PR   27-APR-1999;   99US-0131291.
PR   04-MAY-1999;   99US-0132371.
PR   04-MAY-1999;   99US-0132379.
PR   04-MAY-1999;   99US-0132383.
PR   25-MAY-1999;   99US-0135750.
PR   08-JUN-1999;   99US-0138166.
PR   20-JUL-1999;   99US-0144791.
PR   03-AUG-1999;   99US-0146970.
PR   09-DEC-1999;   99US-0170262.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Desnoyers L,  Eaton DL,  Goddard A,  Godowski PJ,  Gurney AL,  Pan J;
PI   Stewart TA,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2000-628263/60.
DR   P-PSDB; AAB18915.
XX
PT   Novel secreted and transmembrane polypeptides useful for diagnosing
PT   tumour in a mammal, for identifying agonists and antagonists of the
PT   polypeptide and for therapeutic use  -
XX
PS   Claim 2; Fig 13; 222pp; English.
XX
CC   The present sequence encodes a secreted or transmembrane polypeptide.
CC   The specification describes polypeptides designated PRO1484, PRO4334,
CC   PRO1122, PRO1889, PRO1890, PRO1887, PRO1785, PRO4353, PRO4357, PRO4405,
CC   PRO4356, PRO4352, PRO4380, PRO4354, PRO4408, PRO5737, PRO4425, PRO5990,
CC   PRO6030, PRO4424, PRO4422, PRO4430 and PRO4499. PRO1889 polypeptide is
CC   useful for diagnosing tumour in a mammal. The polypeptides, their
CC   agonists and antagonists are useful treating a condition associated with
CC   expression or activity of the polypeptide. Conditions treated include
CC   obesity, diabetes or hyper-or hypo-insulinemia. The polypeptides are
CC   capable of inducing proliferation of mammalian kidney mesangial cells
CC   and are therefore useful for treating kidney disorders associated with
CC   decreased mesangial cell function such as Bergers disease or other
CC   nephropathies associated with Schonlein-Henoch purpura, celiac disease,
CC   dermatitis herpetiformis or Crohns disease. The nucleic acids may be used
CC   to generate transgenic animals for use in development and screening of
CC   therapeutically useful reagents and also for chromosome identification
CC   and tissue typing.
XX
SQ   Sequence 1342 BP; 435 A; 242 C; 258 G; 407 T; 0 other;


  Query Match             15.8%;  Score 169.8;  DB 21;  Length 1342;
  Best Local Similarity   59.0%;  Pred. No. 5.6e-36;
  Matches  291;  Conservative    0;  Mismatches  202;  Indels    0;  Gaps    0;

Qy      97 CTTCTACGACTTCAAGGCGGTCAACATCCGGGGCAAACTGGTGTCGCTGGAGAAGTACCG 156
           ||| || | |||  | | |    |       || | |   || || ||||| |||||
Db     139 cttttatgcctttgaagtgaaggatgcaaaaggaagaactgtttctctggaaaagtataa 198

Qy     157 CGGATCGGTGTCCCTGGTGGTGAATGTGGCCAGCGAGTGCGGCTTCACAGACCAGCACTA 216
             ||    || || || || || || |||||||| || |||    ||||||||    | ||
Db     199 aggcaaagtttcactagttgtaaacgtggccagtgactgccaactcacagacagaaatta 258

Qy     217 CCGAGCCCTGCAGCAGCTGCAGCGAGACCTGGGCCCCCACCACTTCAACGTGCTCGCCTT 276
```

```
Db    259 cttagggctgaaggaactgcacaaagagtttggaccatcccacttcagcgtgttggcttt 318

Qy    277 CCCCTGCAACCAGTTTGGCCAACAGGAGCCTGACAGCAACAAGGAGATTGAGAGCTTTGC 336

Db    319 tccctgcaatcagtttggagaatcggagccccgcccaagcaaggaagtagaatcttttgc 378

Qy    337 CTGCCGCACCTACAGTGTCTCATTCCCCATGTTTAGCAAGATTGCAGTCACCGGTACTGG 396

Db    379 aagaaaaaactacggagtaactttccccatcttccacaagattaagattctaggatctga 438

Qy    397 TGCCCATCCTGCCTTCAAGTACCTGGCCCAGACTTCTGGGAAGGAGCCCACCTGGAACTT 456

Db    439 aggagaacctgcatttagatttcttgttgattcttcaaagaaggaaccaaggtggaattt 498

Qy    457 CTGGAAGTACCTAGTAGCCCCAGATGGAAAGGTGGTAGGGGCTTGGGACCCAACTGTGTC 516

Db    499 ttggaagtatcttgtcaaccctgagggtcaagttgtgaagttctggaggccagaggagcc 558

Qy    517 AGTGGAGGAGGTCAGACTCCAGATCACAGCGCTCGTGAGGAAGCTCATCCTACTGAAGCG 576

Db    559 cattgaagtcatcaggcctgacatagcagctctggttagacaagtgatcataaaaaagaa 618

Qy    577 AGAAGACTTATAA 589

Db    619 agaggatctatga 631


Search completed: August 25, 2002, 06:15:39
Job time: 3774 sec
```